Asymmetric piperazine-based cationic lipids
By developing cationic lipids that are easy to synthesize and contain improved biodegradable groups, the encapsulation efficiency and toxicity of cationic lipids when delivering nucleic acids in the body are solved, efficient and safe delivery of nucleic acids is achieved, and therapeutic effect and safety are improved. .
Patent Information
- Application Number
- CN202380028029.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-16
- Filing Date
- 2023-03-15
- Publication Date
- 2024-11-08
AI Technical Summary
In the prior art, it is difficult to achieve efficient encapsulation and safe release of cationic lipids when delivering nucleic acids in vivo, and there is a risk of toxic by-products, affecting the therapeutic effect and safety.
A cationic lipid that can be synthesized by easily available starting reagents has high encapsulation efficiency and contains improved biodegradable groups such as ester and disulfide bonds for in vivo delivery of nucleic acids to form pharmaceutically acceptable salt form.
Efficient nucleic acid encapsulation and safe in vivo delivery are achieved, reducing the risk of toxicity and improving the biocompatibility and safety of therapeutic agents.
Smart Images

Figure CN118922409A_ABST
Abstract
Description
Cross-reference of related applications
[0001] This application claims priority to U.S. Provisional Application No. 63 / 320,503, filed March 16, 2022, the disclosure of which is incorporated herein by reference. Background Technology
[0002] Nucleic acid delivery has been extensively investigated as a potential treatment option for certain disease conditions. In particular, messenger RNA (mRNA) therapy has become an increasingly important option for treating a variety of diseases, including those associated with deficiencies in one or more proteins.
[0003] Efficient delivery of liposome-encapsulated nucleic acids remains an active area of research. Cationic lipid components play a crucial role in promoting efficient nucleic acid encapsulation during liposome loading. Furthermore, cationic lipids can play an important role in the efficient release of nucleic acid cargo from liposomes into the cytoplasm of target cells. Various cationic lipids suitable for in vivo applications have been developed. However, there is still a need to identify lipids that can be efficiently synthesized inexpensively without forming potentially toxic byproducts. Summary of the Invention
[0004] The present invention particularly provides cationic lipid compounds for in vivo delivery of therapeutic agents, such as nucleic acids. These compounds are intended for efficient in vivo delivery while maintaining a favorable toxicity profile.
[0005] The cationic lipids of the present invention can be synthesized from readily available starting reagents. The cationic lipids of the present invention also exhibit unexpectedly high encapsulation efficiency. The cationic lipids of the present invention also contain cleavable groups (e.g., esters and disulfide bonds) to improve biodegradability and thus contribute to their favorable toxicity profile.
[0006] In one aspect, this paper provides cationic lipids having a structure according to formula (I′): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
[0007] In one respect, this article provides cationic lipids of formula (I'z) that correspond to compounds of formula (I'), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0008] In one respect, this article provides cationic lipids having a structure according to formula (II'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R is selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0009] In one respect, this article provides cationic lipids of formula (II'z) that correspond to compounds of formula (II'), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0010] In one respect, this article provides cationic lipids having a structure according to formula (III'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
[0011] In one respect, this article provides cationic lipids of formula (III'z) that correspond to compounds of formula (III'), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0012] In one aspect, this paper provides cationic lipids having a structure according to formula (IV'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0013] In one respect, this article provides cationic lipids of formula (IV'z) that correspond to compounds of formula (IV'), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0014] In one aspect, this paper provides cationic lipids having a structure according to formula (V'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R AR B R C and R D Selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
[0015] In one respect, this article provides cationic lipids of formula (V'z) that correspond to compounds of formula (V'), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0016] In one aspect, this paper provides cationic lipids having a structure according to formula (VI'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0017] In one respect, this article provides cationic lipids of formula (VI'z) that correspond to compounds of formula (VI'), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0018] In one aspect, this paper provides cationic lipids having a structure according to formula (VII'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0019] In one respect, this article provides cationic lipids of formula (VII'z) that correspond to compounds of formula (VII'), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0020] In one aspect, this paper provides cationic lipids having a structure according to formula (I): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; and Each 'a' is independently selected from 2, 3, 4, and 5.
[0021] In one respect, this article provides cationic lipids of formula (Iz) that correspond to compounds of formula (I), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0022] In one respect, this article provides cationic lipids having a structure according to formula (II): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R is selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; and c is 3 or 4.
[0023] In one respect, this article provides cationic lipids of formula (IIz) that correspond to compounds of formula (II), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0024] In one respect, this article provides cationic lipids having a structure according to formula (III): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a- Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5.
[0025] In one respect, this article provides cationic lipids of formula (IIIz) that correspond to compounds of formula (III), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0026] In one aspect, this article provides cationic lipids having a structure according to formula (IV): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; and c is 3 or 4.
[0027] In one respect, this article provides cationic lipids of formula (IVz) that correspond to compounds of formula (IV), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0028] In one aspect, this paper provides cationic lipids having a structure according to formula (V): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R AR B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5.
[0029] In one respect, this article provides cationic lipids of formula (Vz) that correspond to compounds of formula (V), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0030] In one aspect, this article provides cationic lipids having a structure according to formula (VI): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; and c is 3 or 4.
[0031] In one respect, this article provides cationic lipids of formula (VIz) that correspond to compounds of formula (VI), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0032] In one aspect, this paper provides cationic lipids having a structure according to formula (VII): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; and c is 3 or 4.
[0033] In one respect, this article provides cationic lipids of formula (VIIz) that correspond to compounds of formula (VII), but wherein a is independently selected from 2, 3, 4, 5 and 6.
[0034] In one aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (I′). In one aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (II'). In one aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (III'). In one aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (IV'). In one aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (V'). In one aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (VI'). In one aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (VII').
[0035] In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (I'z). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (II'z). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (III'z). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (IV'z). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (V'z). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (VI'z). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (VII'z).
[0036] In one aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (I). In another aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (II). In another aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (III). In another aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (IV). In another aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (V). In another aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (VI). In another aspect, this document provides cationic lipids of a pharmaceutically acceptable salt of formula (VII).
[0037] In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (Iz). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (IIz). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (IIIz). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (IVz). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (Vz). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (VIz). In one aspect, this article provides cationic lipids of pharmaceutically acceptable salts of formula (VIIz).
[0038] In one aspect, this document provides compositions comprising the cationic lipids of the present invention, one or more non-cationic lipids, one or more cholesterol-based lipids, and one or more PEG-modified lipids. In another aspect, the compositions are lipid nanoparticles, optionally liposomes.
[0039] In one aspect, compositions comprising the cationic lipids of the present invention can be used in therapeutic applications. Attached Figure Description
[0040] Figure 1 The figure depicts in vivo protein production induced by delivery of mRNA (i.e., hEPO mRNA) using lipid nanoparticles containing compounds B1 or C1 as described herein. As shown in the figure, the use of these compounds induced high levels of in vivo protein production (i.e., hEPO protein) upon administration.
[0041] Figure 2 Describe process 24A.
[0042] Figure 3 Describe process 24B.
[0043] Figure 4 Describe process 25A.
[0044] Figure 5 Describe the process 25B.
[0045] Figure 6 Describe process 26A.
[0046] Figure 7 Describe process 26B.
[0047] Figure 8 Describe process 27A.
[0048] Figure 9 Describe process 27B.
[0049] Figure 10 Describe process 28A.
[0050] Figure 11 Describe process 28B.
[0051] Figure 12 Describe process 29A.
[0052] Figure 13 Describe process 29B.
[0053] Figure 14 Depicting process 29C. Detailed Implementation definition
[0054] To make the present invention more readily understood, certain terms are first defined below. Other definitions of the following and other terms are set forth throughout this specification. Disclosures and other references describing the background art and providing additional details about its practice, which are cited herein, are incorporated by reference.
[0055] Amino acids: As used herein, the term "amino acid" in its broadest sense refers to any compound and / or substance that can be incorporated into a polypeptide chain. In some embodiments, amino acids have the general formula H₂N-C(H)(R)-COOH. In some embodiments, amino acids are naturally occurring amino acids. In some embodiments, amino acids are synthetic amino acids; in some embodiments, amino acids are d-amino acids; in some embodiments, amino acids are l-amino acids. "Standard amino acid" refers to any of the twenty standard l-amino acids commonly found in naturally occurring peptides. "Non-standard amino acid" refers to any amino acid other than standard amino acids, whether it is prepared synthetically or obtained from a natural source. As used herein, "synthetic amino acid" encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and / or substitutes. Amino acids, including carboxyl and / or amino-terminal amino acids in peptides, can be modified by methylation, amidation, acetylation, protecting groups, and / or substitution with other chemical groups that can alter the cyclic half-life of the peptide without adversely affecting its activity. Amino acids can participate in disulfide bonds. Amino acids may contain one or more post-translational modifications, such as binding to one or more chemical entities (e.g., methyl, acetate, acetyl, phosphate, formyl moiety, isoprene-like group, sulfate group, polyethylene glycol moiety, lipid moiety, carbohydrate moiety, biotin moiety, etc.). The term "amino acid" is used interchangeably with "amino acid residue" and can refer to free lysine and / or amino acid residues of peptides. It is obvious from the context in which the term is used that it refers to a free lysine or peptide residue.
[0056] Animal: As used herein, the term "animal" means any member of the animal kingdom. In some embodiments, "animal" means a human being at any developmental stage. In some embodiments, "animal" means a non-human animal at any developmental stage. In some embodiments, non-human animals are mammals (e.g., rodents, mice, rats, rabbits, monkeys, dogs, cats, sheep, bovids, primates, and / or pigs). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and / or worms. In some embodiments, animals may be transgenic animals, genetically engineered animals, and / or strains.
[0057] Approximately or about: As used herein, the terms “approximately” or “about” apply to one or more values of interest, meaning values similar to the stated reference value. In some embodiments, unless otherwise stated or otherwise apparent from the context, the terms “approximately” or “about” refer to a range of values that are within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the stated reference value in any direction (whether greater than or less than) 100% of the possible value.
[0058] Bioactivity: As used herein, the term “bioactivity” refers to the characteristic of any agent that is active in a biological system, and particularly in an organism. For example, an agent that has a biological effect on an organism when administered to that organism is considered to be bioactive.
[0059] Delivery: As used herein, the term “delivery” encompasses both local and systemic delivery. For example, mRNA delivery includes the delivery of mRNA to a target tissue where it is expressed and retained in the target tissue (also known as “local distribution” or “local delivery”), and the delivery of mRNA to a target tissue where it is expressed and secreted into the patient’s circulatory system (e.g., serum), and distributed systemically and absorbed by other tissues (also known as “systemic distribution” or “systemic delivery”).
[0060] Expression: As used herein, “expression” of a nucleic acid sequence refers to the translation of mRNA into a polypeptide, the assembly of multiple polypeptides into a complete protein (e.g., an enzyme), and / or post-translational modifications of a polypeptide or a fully assembled protein (e.g., an enzyme). In this application, the terms “expression” and “production” and their grammatical equivalents are used interchangeably.
[0061] Functionality: As used herein, a "functional" biomolecule is a form of biomolecule that exhibits its properties and / or activities, characterized by those properties and / or activities.
[0062] Half-life: As used herein, the term “half-life” is the time required for the concentration or activity of a substance, such as a nucleic acid or protein, to decrease to half of its value at the beginning of the period.
[0063] Supporting lipids: As used herein, the term "supporting lipid" refers to any neutral or zwitterionic lipid material, including cholesterol. Without wishing to be bound by any particular theory, supporting lipids can increase the stability, rigidity, and / or fluidity of lipid bilayers / nanoparticles.
[0064] Improved, increased, or decreased: As used herein, the terms “improved,” “increased,” or “decreased,” or their grammatical equivalents, indicate values relative to baseline measurements, such as measurements in the same individual prior to initiation of the treatment described herein, or measurements in control individuals (or multiple control individuals) in the absence of the treatment described herein. A “control individual” is an individual with the same form of disease as the treated individual and of the same age.
[0065] In vitro: As used herein, the term “in vitro” refers to events that occur in an artificial environment, such as in test tubes or reaction vessels, in cell cultures, etc., rather than in multicellular organisms.
[0066] In vivo: As used herein, the term "in vivo" refers to events occurring within multicellular organisms such as humans and non-human animals. In the context of cell-based systems, the term can be used to refer to events occurring within living cells (as opposed to, for example, in vitro systems).
[0067] Separated: As used herein, the term “separated” means a substance and / or entity that has been (1) separated from at least some of the components that were initially bound to it (whether in nature and / or in an experimental setting), and / or (2) artificially produced, prepared, and / or manufactured. Separated substances and / or entities may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components that were initially bound to it. In some embodiments, the isolated reagent is about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is considered "pure" if it is substantially free of other components. As used herein, the percentage of purity of the isolated substance and / or entity should not include excipients (e.g., buffer solutions, solvents, water, etc.).
[0068] Liposomes: As used herein, the term "liposome" refers to any layered, multilayered, or solid nanoparticle vesicle. Typically, as used herein, liposomes can be formed by mixing one or more lipids or by mixing one or more lipids with a polymer. In some embodiments, liposomes suitable for use in the present invention contain cationic lipids and optionally non-cationic lipids, optionally cholesterol-based lipids, and / or optionally PEG-modified lipids.
[0069] Messenger RNA (mRNA): As used herein, the term “messenger RNA (mRNA)” or “mRNA” refers to a polynucleotide encoding at least one polypeptide. As used herein, mRNA encompasses both modified and unmodified RNA. The term “modified mRNA” is associated with mRNA containing at least one chemically modified nucleotide. mRNA may contain one or more coding and non-coding regions. mRNA may be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, for example, in the case of chemically synthesized molecules, mRNA may contain nucleoside analogs, such as analogs having chemically modified bases or sugars, backbone modifications, etc. Unless otherwise indicated, mRNA sequences are presented in a 5' to 3' orientation. In some embodiments, the mRNA is or contains a natural nucleoside (e.g., adenosine, guanosine, cytidine, uridine); or a nucleoside analogue (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C5-propynyl-cytidine, C5-propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine). Glycosides, 2-aminoadenosine, 7-deadenosine, 7-deadenosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g. methylated bases); intercalated bases; modified sugars (e.g. 2'-fluororibose, ribose, 2'-deoxyribose, arabinose and hexose); and / or modified phosphate groups (e.g. thiophosphate and 5'-N-aminophosphite linkages).
[0070] Nucleic acid: As used herein, the term "nucleic acid" in its broadest sense refers to a polynucleotide chain or any compound and / or substance incorporable therein. In some embodiments, nucleic acid is a compound and / or substance that is a polynucleotide chain or can be incorporated therein via a phosphodiester bond. In some embodiments, "nucleic acid" refers to an individual nucleic acid residue (e.g., nucleotides and / or nucleosides). In some embodiments, "nucleic acid" refers to a polynucleotide chain containing an individual nucleic acid residue. In some embodiments, "nucleic acid" encompasses RNA as well as single-stranded and / or double-stranded DNA and / or cDNA. In some embodiments, "nucleic acid" encompasses ribonucleic acid (RNA), including but not limited to any one or more of the following: interfering RNA (RNAi), small interfering RNA (siRNA), short hairpin RNA (shRNA), antisense RNA (aRNA), messenger RNA (mRNA), modified messenger RNA (mmRNA), long non-coding RNA (lncRNA), microRNA (miRNA), multimeric coding nucleic acid (MCNA), polymeric coding nucleic acid (PCNA), guide RNA (gRNA), and CRISPR RNA (crRNA). In some embodiments, "nucleic acid" encompasses deoxyribonucleic acid (DNA), including but not limited to one or more of the following: single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), and complementary DNA (cDNA). In some embodiments, "nucleic acid" encompasses both RNA and DNA. In embodiments, DNA may be in the following forms: antisense DNA, plasmid DNA, a portion of plasmid DNA, pre-condensed DNA, polymerase chain reaction (PCR) product, vector (e.g., P1, PAC, BAC, YAC, artificial chromosome), expression cassette, chimeric sequence, chromosomal DNA, or derivatives of these groups.In the implementation scheme, RNA may be in the following forms: messenger RNA (mRNA), ribosomal RNA (rRNA), message recognition particle RNA (7SL RNA or SRP RNA), transfer RNA (tRNA), transfer messenger RNA (tmRNA), small nucleus RNA (snRNA), small nucleolar RNA (snoRNA), SmY RNA, small Cajal body-specific RNA (scaRNA), guide RNA (gRNA), ribonuclease P (RNase P), Y RNA, telomerase RNA component (TERC), splicing leader RNA (SL RNA), antisense RNA (aRNA or asRNA), cis-native antisense transcript (cis-NAT), CRISPR RNA (crRNA), long noncoding RNA (lncRNA), microRNA (miRNA), piwi-interacting RNA (piRNA), small interfering RNA (siRNA), lateral-acting siRNA (tasiRNA), repeat-associated siRNA (rasiRNA), 73KRNA, retrotranscribed transposons, viral genomes, viroids, satellite RNA, or derivatives of these groups. In some implementations, nucleic acids are mRNAs encoding proteins (such as enzymes).
[0071] Patient: As used herein, the terms "patient" or "individual" refer to any organism to which the provided composition may be administered, for example, for experimental, diagnostic, preventative, cosmetic, and / or therapeutic purposes. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, the patient is a human. Humans include both prenatal and postnatal forms.
[0072] Pharmaceutically acceptable: As used herein, the term “pharmaceutically acceptable” means a substance that, within the bounds of reasonable medical judgment, is suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reactions or other problems or complications, and is commensurate with a reasonable benefit / risk ratio.
[0073] Pharmaceutically acceptable salts: Pharmaceutically acceptable salts are well known in the art. For example, SMBerge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from those suitable for inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are amino salts formed with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid), or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid), or by using other methods used in the art (such as ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, hydrogen sulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, disglucuronate, dodecyl sulfate, ethanesulfonate, formate, transbutenedioate, glucono-heptahydrate, glyceryl phosphate, gluconate, hemisulfate, heptahydrate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, dihydroxynaphthalate, pectate, persulfate, 3-phenylpropionate, phosphate, p-pentanoate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and similar salts. Salts derived from suitable bases include alkali metal salts, alkaline earth metal salts, ammonium salts, and N salts. + (C 1-4 Alkyl)4 salts. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and similar salts. Where appropriate, other pharmaceutically acceptable salts include non-toxic ammonium. Quaternary ammonium salts and amine cations formed using relative ions such as halide, hydroxide, carboxyl, sulfate, phosphate, nitrate, sulfonate, and arylsulfonate ions. Other pharmaceutically acceptable salts include those formed by the quaternization of amines using a suitable electrophilic agent (e.g., alkyl halide) to form quaternized alkylated amino salts.
[0074] Systemic distribution or delivery: As used herein, the terms “systemic distribution” or “systemic delivery” or their grammatical equivalents refer to a mechanism or method of delivery or distribution that affects the whole body or the entire organism. Typically, systemic distribution or delivery is accomplished via the body’s circulatory system, such as blood flow. This contrasts with the definition of “local distribution or delivery.”
[0075] Individual: As used herein, the term “individual” means human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate). Human includes both prenatal and postnatal forms. In many embodiments, the individual is human. An individual can be a patient, which refers to a human presented to a healthcare provider for the diagnosis or treatment of a disease. The term “individual” may be used interchangeably with “individual” or “patient” herein. An individual may have or be susceptible to a disease or condition, but may or may not exhibit symptoms of that disease or condition.
[0076] In essence: As used herein, the term “in essence” refers to a qualitative state that presents all or nearly all limits or degrees of the feature or characteristic of interest. Those skilled in biotechnology will understand that biological and chemical phenomena rarely (if ever) proceed to completeness or achieve or avoid absolute results. Therefore, the term “in essence” is used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0077] Target tissue: As used herein, the term "target tissue" refers to any tissue affected by the disease to be treated. In some implementations, target tissue includes those tissues that exhibit disease-related lesions, symptoms, or characteristics.
[0078] Therapeutic effective amount: As used herein, the term "therapeutic effective amount" means an amount sufficient to treat, diagnose, prevent, and / or delay the onset of symptoms of a disease, condition, and / or symptom when administered to an individual who suffers from or is susceptible to the disease, condition, and / or symptom. Those skilled in the art will understand that a therapeutic effective amount is typically administered via a dosing regimen comprising at least one unit dose.
[0079] Treatment: As used herein, the terms “treat,” “treatment,” or “treatment” mean any method used to partially or completely alleviate, improve, reduce, suppress, prevent, delay the onset of one or more symptoms or features of a particular disease, condition, and / or symptom, reduce its severity, and / or reduce its incidence. Treatment is administered to individuals who do not present with signs of disease and / or only with early signs of disease in order to reduce their risk of developing lesions associated with that disease. Chemical definition
[0080] Acyl group: As used herein, the term "acyl group" refers to R Z -(C=O)-, where R Z For example, any alkyl, alkenyl, ynyl, heteroalkyl, or heteroalkylene.
[0081] Aliphatic: As used in this article, the term aliphatic refers to C1-C 50Hydrocarbons, including both saturated and unsaturated hydrocarbons. Aliphatic hydrocarbons can be straight-chain, branched-chain, or cyclic. For example, C1-C 20 Aliphatic ali ... 20 Alkyl groups (e.g., straight-chain or branched C1-C) 20 saturated alkyl), C2-C 20 Alkenyl groups (e.g., straight-chain or branched C4-C) 20 Dieneyl, straight-chain or branched C6-C 20 Trienyl groups and their analogues) and C2-C 20 Alkyne groups (e.g., straight-chain or branched C2-C) 20 Alkyne group). C1-C 20 Aliphatic ali ... 20 Cyclic aliphatic (e.g., C3-C) 20 cycloalkyl, C4-C 20 Cycloalkenyl or C8-C 20 (Cycloalkyne). In some embodiments, the aliphatic group may comprise one or more cycloaliphatic groups and / or one or more heteroatoms (such as oxygen, nitrogen, or sulfur), and may optionally be substituted with one or more substituents such as alkyl, halo, alkoxy, hydroxy, amino, aryl, ether, ester, or amide. The aliphatic group is unsubstituted or substituted with one or more substituents as described herein. For example, the aliphatic group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of the following: halogen, -COR", -CO2H, -CO2R", -CN, -OH, -OR", -OCOR', -OCO2R", -NH2, -NHR", -N(R")2, -SR", or -SO2R", wherein each example of R is independently C1-C1. 20 Aliphatic (e.g., C1-C) 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In the embodiments, R” is independently an unsubstituted alkyl group (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In embodiments, "R" is independently an unsubstituted C1-C3 alkyl group. In embodiments, the aliphatic group is unsubstituted. In embodiments, the aliphatic group does not include any heteroatoms. Alkyl: As used herein, the term "alkyl" means a non-cyclic straight-chain and branched hydrocarbon group, such as "C1-C3 alkyl". 30"Alkyl" refers to an alkyl group having 1 to 30 carbon atoms. Alkyl groups can be straight-chain or branched-chain. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, dibutyl, tert-butyl, pentyl, isopentyl, tripentyl, hexyl, isohexyl, etc. The term "lower alkyl" means a straight-chain or branched alkyl group having 1 to 6 carbon atoms. Other alkyl groups will readily be apparent to those skilled in the art in view of the benefits of the present invention. Alkyl groups can be unsubstituted or substituted with one or more substituents as described herein. For example, alkyl groups can be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of the following: halogen, -COR", -CO2H, -CO2R", -CN, -OH, -OR", -OCOR', -OCO2R", -NH2, -NHR", -N(R")2, -SR" or -SO2R", wherein each example of R" is independently C1-C 20 Aliphatic (e.g., C1-C) 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In the embodiments, R” is independently an unsubstituted alkyl group (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In embodiments, "R" independently refers to an unsubstituted C1-C3 alkyl. In embodiments, the alkyl group is substituted (e.g., substituted with 1, 2, 3, 4, 5, or 6 substituents as described herein). In embodiments, the alkyl group is substituted with a -OH group and may also be referred to herein as "hydroxyalkyl", wherein the prefix indicates a -OH group and "alkyl" is as described herein.
[0082] As used herein, "alkyl" also refers to a straight-chain or branched saturated hydrocarbon group having 1 to 50 carbon atoms ("C1-C50"). 50 Alkyl group (“alkyl”). In some embodiments, the alkyl group has 1 to 40 carbon atoms (“C1-C4”). 40 Alkyl group (“alkyl”). In some embodiments, the alkyl group has 1 to 30 carbon atoms (“C1-C3”). 30 Alkyl group (“alkyl”). In some embodiments, the alkyl group has 1 to 20 carbon atoms (“C1-C2”). 20 Alkyl group (“alkyl”). In some embodiments, the alkyl group has 1 to 10 carbon atoms (“C1-C1”). 10The alkyl group has 1 to 9 carbon atoms (“C1-C9 alkyl”). In some embodiments, the alkyl group has 1 to 8 carbon atoms (“C1-C8 alkyl”). In some embodiments, the alkyl group has 1 to 7 carbon atoms (“C1-C7 alkyl”). In some embodiments, the alkyl group has 1 to 6 carbon atoms (“C1-C6 alkyl”). In some embodiments, the alkyl group has 1 to 5 carbon atoms (“C1-C5 alkyl”). In some embodiments, the alkyl group has 1 to 4 carbon atoms (“C1-C4 alkyl”). In some embodiments, the alkyl group has 1 to 3 carbon atoms (“C1-C3 alkyl”). In some embodiments, the alkyl group has 1 to 2 carbon atoms (“C1-C2 alkyl”). In some embodiments, the alkyl group has 1 carbon atom (“C1 alkyl”). In some embodiments, the alkyl group has 2 to 6 carbon atoms (“C2-C6 alkyl”). Examples of C1-C6 alkyl groups include, but are not limited to, methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), dibutyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tripentyl (C5), and n-hexyl (C6). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (C8), and the like. Unless otherwise stated, each example of an alkyl group is independently unsubstituted (“unsubstituted alkyl”) or substituted with one or more substituents (“substituted alkyl”). In some embodiments, the alkyl group is an unsubstituted C1-C6 alkyl group. 50 Alkyl group. In some embodiments, the alkyl group is a substituted C1-C alkyl group. 50 alkyl.
[0083] The suffix "-ene" attached to a group indicates that the group is a divalent moiety. For example, arylene is the divalent moiety of an aryl group, and heteroarylene is the divalent moiety of a heteroaryl group.
[0084] Alkylene: As used herein, the term "alkylene" refers to a saturated divalent straight-chain or branched hydrocarbon group, such as methylene, ethylene, isopropylene, and the like. Similarly, as used herein, the term "alkenylene" refers to an unsaturated divalent straight-chain or branched hydrocarbon group having one or more unsaturated carbon-carbon double bonds (which may be present at any stable point along the chain), and the term "alkynylene" herein refers to an unsaturated divalent straight-chain or branched hydrocarbon group having one or more unsaturated carbon-carbon triple bonds (which may be present at any stable point along the chain). In some embodiments, the alkylene, alkenylene, or alkynylene group may comprise one or more cycloaliphatic and / or one or more heteroatoms (such as oxygen, nitrogen, or sulfur), and may optionally be substituted with one or more substituents such as alkyl, halogen, alkoxy, hydroxyl, amino, aryl, ether, ester, or amide. For example, the alkylene, alkenylene, or ynylene group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently chosen substituents) of the following: halogen, -COR", -CO2H, -CO2R", -CN, -OH, -OR", -OCOR", -OCO2R", -NH2, -NHR", -N(R")2, -SR", or -SO2R", wherein each example of R is independently C1-C. 20 Aliphatic (e.g., C1-C) 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In the embodiments, R” is independently an unsubstituted alkyl group (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In embodiments, "R" is independently an unsubstituted C1-C3 alkyl. In some embodiments, the alkylene, alkenyl, or ynylene is unsubstituted. In some embodiments, the alkylene, alkenyl, or ynylene does not include any heteroatoms. Alkenyl: As used herein, "alkenyl" means any straight or branched hydrocarbon chain having one or more unsaturated carbon-carbon double bonds (which may be present at any stable point along the chain), such as "C2-C". 30"Alkenyl" refers to an alkenyl group having 2-30 carbon atoms. For example, alkenyl groups include prop-2-enyl, but-2-enyl, but-3-enyl, 2-methylprop-2-enyl, hex-2-enyl, hex-5-enyl, 2,3-dimethylbut-2-enyl, and the like. In embodiments, the alkenyl group comprises 1, 2, or 3 carbon-carbon double bonds. In embodiments, the alkenyl group comprises a single carbon-carbon double bond. In embodiments, multiple double bonds are conjugated (e.g., 2 or 3). The alkenyl group may be unremoved. The alkenyl group may be substituted with one or more substituents as described herein. For example, the alkenyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of the following: halogen, -COR", -CO2H, -CO2R", -CN, -OH, -OR", -OCOR", -OCO2R", -NH2, -NHR", -N(R")2, -SR", or -SO2R", wherein each example of R is independently C1-C. 20 Aliphatic (e.g., C1-C) 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In the embodiments, R” is independently an unsubstituted alkyl group (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In embodiments, "R" is independently an unsubstituted C1-C3 alkyl. In embodiments, the alkenyl group is unsubstituted. In embodiments, the alkenyl group is substituted (e.g., substituted with 1, 2, 3, 4, 5, or 6 substituents as described herein). In embodiments, the alkenyl group is substituted with a -OH group and may also be referred to herein as "hydroxyalkenyl," wherein the prefix indicates a -OH group and "alkenyl" is as described herein.
[0085] As used herein, "alkenyl" also refers to a straight-chain or branched-chain hydrocarbon group ("C2-C") having 2 to 50 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds). 50 Alkenyl group (“Alkenyl”). In some embodiments, the alkenyl group has 2 to 40 carbon atoms (“C2-C”). 40 Alkenyl group (“Alkenyl”). In some embodiments, the alkenyl group has 2 to 30 carbon atoms (“C2-C”). 30 Alkenyl group (“Alkenyl”). In some embodiments, the alkenyl group has 2 to 20 carbon atoms (“C2-C”). 20 Alkenyl group (“Alkenyl”). In some embodiments, the alkenyl group has 2 to 10 carbon atoms (“C2-C”). 10The alkenyl group has 2 to 9 carbon atoms (“C2-C9 alkenyl”). In some embodiments, the alkenyl group has 2 to 8 carbon atoms (“C2-C8 alkenyl”). In some embodiments, the alkenyl group has 2 to 7 carbon atoms (“C2-C7 alkenyl”). In some embodiments, the alkenyl group has 2 to 6 carbon atoms (“C2-C6 alkenyl”). In some embodiments, the alkenyl group has 2 to 5 carbon atoms (“C2-C5 alkenyl”). In some embodiments, the alkenyl group has 2 to 4 carbon atoms (“C2-C4 alkenyl”). In some embodiments, the alkenyl group has 2 to 3 carbon atoms (“C2-C3 alkenyl”). In some embodiments, the alkenyl group has 2 carbon atoms (“C2 alkenyl”). One or more carbon-carbon double bonds may be located internally. Examples of C2-C4 alkenyl groups include, but are not limited to, vinyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-C6 alkenyl groups include the aforementioned C2-C4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Other examples of alkenyl groups include heptenyl (C7), octenyl (C8), octtrienyl (C8), and the like. Unless otherwise specified, each example of an alkenyl group is independently unsubstituted (“unsubstituted alkenyl”) or substituted with one or more substituents (“substituted alkenyl”). In some embodiments, the alkenyl group is an unsubstituted C2-C4 alkenyl group. 50 Alkenyl group. In some embodiments, the alkenyl group is a substituted C2-C group. 50 Alkenyl group.
[0086] Alkynyl: As used herein, "alkynyl" means any hydrocarbon chain that is straight-chain or branched and has one or more carbon-carbon triple bonds present at any stable point along the chain, such as "C2-C". 30 "Alynyl" refers to an alkynyl group having 2-30 carbon atoms. Examples of alkynyl groups include prop-2-alkynyl, but-2-alkynyl, but-3-alkynyl, pent-2-alkynyl, 3-methylpent-4-alkynyl, hex-2-alkynyl, hex-5-alkynyl, etc. In embodiments, the alkynyl group comprises a carbon-carbon triple bond. The alkynyl group may be unsubstituted or substituted with one or more substituents as described herein. For example, the alkynyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of the following: halogen, -COR", -CO2H, -CO2R", -CN, -OH, -OR", -OCOR", -OCO2R", -NH2, -NHR", -N(R)2, -SR, or -SO2R", wherein each example of R is independently C1-C1. 20 Aliphatic (e.g., C1-C) 20Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In the embodiments, R” is independently an unsubstituted alkyl group (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl). In embodiments, R” is independently an unsubstituted C1-C3 alkyl. In embodiments, the alkynyl group is unsubstituted. In embodiments, the alkynyl group is substituted (e.g., substituted with 1, 2, 3, 4, 5 or 6 substituents as described herein).
[0087] As used herein, “alkynyl” also refers to a straight-chain or branched hydrocarbon group (“C2-C”) having 2 to 50 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) and optionally one or more double bonds (e.g., 1, 2, 3, or 4 double bonds). 50 The alkynyl group ("alkynyl group"). An alkynyl group having one or more triple bonds and one or more double bonds is also called an "alkynyl group". In some embodiments, the alkynyl group has 2 to 40 carbon atoms ("C2-C3"). 40 The alkynyl group (“acetylation”) is present in some embodiments. In some embodiments, the alkynyl group has 2 to 30 carbon atoms (“C2-C”). 30 The alkynyl group (“C2-C”) is present in some embodiments. In some embodiments, the alkynyl group has 2 to 20 carbon atoms (“C2-C”). 20 The alkynyl group (“C2-C”) is present in some embodiments. In some embodiments, the alkynyl group has 2 to 10 carbon atoms (“C2-C”). 10The alkynyl group has 2 to 9 carbon atoms (“C2-C9 alkynyl”). In some embodiments, the alkynyl group has 2 to 8 carbon atoms (“C2-C8 alkynyl”). In some embodiments, the alkynyl group has 2 to 7 carbon atoms (“C2-C7 alkynyl”). In some embodiments, the alkynyl group has 2 to 6 carbon atoms (“C2-C6 alkynyl”). In some embodiments, the alkynyl group has 2 to 5 carbon atoms (“C2-C5 alkynyl”). In some embodiments, the alkynyl group has 2 to 4 carbon atoms (“C2-C4 alkynyl”). In some embodiments, the alkynyl group has 2 to 3 carbon atoms (“C2-C3 alkynyl”). In some embodiments, the alkynyl group has 2 carbon atoms (“C2 alkynyl”). Multiple carbon-triple bonds may be internal (e.g., in 2-butynyl) or terminal (e.g., in 1-butynyl). Examples of C2-C4 alkynes include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2-C6 alkynes include the aforementioned C2-C4 alkynes as well as pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynes include heptyynyl (C7), octyynyl (C8), and the like. Unless otherwise specified, each example of an alkyne is independently unsubstituted (“unsubstituted alkyne”) or substituted with one or more substituents (“substituted alkyne”). In some embodiments, the alkyne is an unsubstituted C2-C... 50 Alkyne group. In some embodiments, the alkynyl group is a substituted C2-C group. 50 Alkyne group.
[0088] Aryl: The term "aryl" used alone or as part of a larger portion (such as in "araneyl") refers to a monocyclic, bicyclic, or tricyclic carbocyclic system having a total of six to fourteen ring members, wherein the ring system has a single connection point with the rest of the molecule, at least one ring in the system is aromatic, and each ring in the system contains 4 to 7 ring members. In embodiments, the aryl group has 6 ring carbon atoms ("C6 aryl", e.g., phenyl). In some embodiments, the aryl group has 10 ring carbon atoms ("C6 aryl"). 10 "Aryl", such as naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, the aryl group has 14 cyclic carbon atoms ("C"). 14 "Aryl" (e.g., anthracene). "Aryl" also includes ring systems in which an aryl ring as defined above is fused with one or more carbocyclic or heterocyclic groups, wherein the linking group or linking point is on the aryl ring, and in such cases, the number of carbon atoms continues to indicate the number of carbon atoms in the aryl ring system. Exemplary aryl groups include phenyl, naphthyl, and anthracene.
[0089] As used herein, "aryl" also refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system group having 6-14 ring carbon atoms and zero heteroatoms donated to the aromatic ring system (e.g., having 6, 10, or 14 π electrons in the ring array) ("C6-C"). 14 Aryl group (“C6 aryl”). In some embodiments, the aryl group has 6 ring carbon atoms (“C6 aryl”; for example, phenyl). In some embodiments, the aryl group has 10 ring carbon atoms (“C6 aryl”). 10 Aryl; for example, naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, the aryl group has 14 cyclic carbon atoms (“C”). 14 "Aryl"; for example, anthracene. "Aryl" also includes ring systems in which an aryl ring as defined above is fused with one or more carbocyclic or heterocyclic groups, wherein the linking group or linking point is on the aryl ring, and in such cases, the number of carbon atoms continues to indicate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each example of aryl is independently unsubstituted ("unsubstituted aryl") or substituted with one or more substituents ("substituted aryl"). In some embodiments, the aryl is unsubstituted C6-C. 14 Aryl group. In some embodiments, the aryl group is a substituted C6-C group. 14 Aryl.
[0090] arylene: As used herein, the term "arylene" refers to a divalent aryl group (i.e., one with two bonding sites with the molecule). Exemplary arylene groups include phenylene (e.g., unsubstituted or substituted phenylene).
[0091] Carbocyclic group: As used herein, "carbocyclic group" or "carbocyclic" refers to a non-aromatic ring system having 3 to 10 ring carbon atoms ("C3-C"). 10 The carbocyclic group comprises a non-aromatic cyclic hydrocarbon group with zero heteroatoms. In some embodiments, the carbocyclic group has 3 to 8 cyclic carbon atoms (“C3-C8 carbocyclic”). In some embodiments, the carbocyclic group has 3 to 7 cyclic carbon atoms (“C3-C7 carbocyclic”). In some embodiments, the carbocyclic group has 3 to 6 cyclic carbon atoms (“C3-C6 carbocyclic”). In some embodiments, the carbocyclic group has 4 to 6 cyclic carbon atoms (“C4-C6 carbocyclic”). In some embodiments, the carbocyclic group has 5 to 6 cyclic carbon atoms (“C5-C6 carbocyclic”). In some embodiments, the carbocyclic group has 5 to 10 cyclic carbon atoms (“C5-C6 carbocyclic”). 10Carbocyclic groups (C3-C6) are included, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and others like these. Examples of C3-C8 carbocyclic groups include, but are not limited to, the aforementioned C3-C6 carbocyclic groups, as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptanetrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptyl (C7), bicyclo[2.2.2]octyl (C8), and others like these. Examples of C3-C... 10 Carbocyclic groups include, but are not limited to, the aforementioned C3-C8 carbocyclic groups, as well as cyclononyl (C9), cyclononenyl (C9), and cyclodecyl (C9). 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthyl (C9) 10 ), spiro[4.5]decyl(C 10 ) and similar. As illustrated in the foregoing embodiments, in some embodiments, the carbocyclic group is monocyclic (“monocyclic carbocyclic”) or polycyclic (e.g., containing fused, bridged, or spirocyclic systems, such as bicyclic systems (“bicyclic carbocyclic”) or tricyclic systems (“tricyclic carbocyclic”) and may be saturated or may contain one or more carbon-carbon double or triple bonds. “Carbocyclic” also includes ring systems in which the carbocyclic ring as defined above is fused with one or more aryl or heteroaryl groups, wherein the connection point is on the carbocyclic ring, and in such cases, the number of carbons continues to indicate the number of carbons in the carbocyclic system. Unless otherwise specified, each example of a carbocyclic group is independently unsubstituted (“unsubstituted carbocyclic”) or substituted with one or more substituents (“substituted carbocyclic”). In some embodiments, the carbocyclic group is unsubstituted C3-C 10 Carbocyclic group. In some embodiments, the carbocyclic group is a substituted C3-C group. 10 Carbon cyclic group.
[0092] In some embodiments, "carbocyclic group" or "carbocyclic ring" is referred to as "cycloalkyl group," that is, a monocyclic saturated carbocyclic group ("C3-C") having 3 to 10 ring carbon atoms. 10 The cycloalkyl group has 3 to 8 cyclic carbon atoms (“C3-C8 cycloalkyl”). In some embodiments, the cycloalkyl group has 3 to 6 cyclic carbon atoms (“C3-C6 cycloalkyl”). In some embodiments, the cycloalkyl group has 4 to 6 cyclic carbon atoms (“C4-C6 cycloalkyl”). In some embodiments, the cycloalkyl group has 5 to 6 cyclic carbon atoms (“C5-C6 cycloalkyl”). In some embodiments, the cycloalkyl group has 5 to 10 cyclic carbon atoms (“C5-C6 cycloalkyl”). 10Cycloalkyl. Examples of C5-C6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). Examples of C3-C6 cycloalkyl groups include the aforementioned C5-C6 cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-C8 cycloalkyl groups include the aforementioned C3-C6 cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each example of a cycloalkyl group is independently unsubstituted (“unsubstituted cycloalkyl”) or substituted with one or more substituents (“substituted cycloalkyl”). In some embodiments, the cycloalkyl group is an unsubstituted C3-C6 cycloalkyl group. 10 Cycloalkyl. In some embodiments, the cycloalkyl group is a substituted C3-C. 10 Cycloalkyl.
[0093] Halogen: As used in this article, the term “halogen” means fluorine, chlorine, bromine or iodine.
[0094] Heteroalkyl: The term "heteroalkyl" refers to a branched or unbranched alkyl, alkenyl, or alkynyl group having 1 to 14 carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, S, and P. Heteroalkyl groups include tertiary amines, secondary amines, ethers, thioethers, amides, thioamides, carbamates, thiocarbamates, hydrazones, imines, phosphate diesters, aminophosphates, sulfonamides, and disulfides. Heteroalkyl groups may optionally include monocyclic, bicyclic, or tricyclic rings, wherein each ring ideally has three to six members. Examples of heteroalkyl groups include polyethers such as methoxymethyl and ethoxyethyl.
[0095] Heteroalkyl: As used herein, the term “heteroalkyl” refers to the divalent form of a heteroalkyl group as described herein.
[0096] Heteroaryl: As used herein, the term “heteroaryl” is a fully unsaturated ring containing a heteroatom, wherein at least one ring atom is a heteroatom, such as, but not limited to, nitrogen and oxygen.
[0097] As used herein, “heteroaryl” also refers to a group having a 5- to 14-membered monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., with a total of 6, 10, or 14 π electrons in the ring array) of a ring system, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus (“5- to 14-membered heteroaryl”). In heteroaryls containing one or more nitrogen atoms, the bonding point may be a carbon or nitrogen atom, where the valence permits. A heteroaryl polycyclic system may include one or more heteroatoms in one or two rings. “Heteroaryl” includes a ring system in which a heteroaryl ring as defined above is fused with one or more carbocyclic or heterocyclic groups, wherein the bonding point is on the heteroaryl ring, and in such cases, the number of ring members continues to indicate the number of ring members in the heteroaryl ring system. "Heteroaryl" also includes ring systems in which a heteroaryl ring as defined above is fused with one or more aryl groups, wherein the linking point is on the aryl or heteroaryl ring, and in such cases, the number of ring members indicates the number of ring members in the fused polycyclic (aryl / heteroaryl) ring system. For polycyclic heteroaryl groups in which one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like), the linking point can be located on either ring, i.e., the ring carrying the heteroatom (e.g., 2-indolyl) or the ring without the heteroatom (e.g., 5-indolyl).
[0098] In some embodiments, the heteroaryl group is a 5- to 10-membered aromatic ring system having a cyclic carbon atom and one or more (e.g., 1, 2, 3, or 4) cyclic heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus (“5- to 10-membered heteroaryl”). In some embodiments, the heteroaryl group is a 5- to 8-membered aromatic ring system having a cyclic carbon atom and one or more (e.g., 1, 2, 3, or 4) cyclic heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus (“5- to 8-membered heteroaryl”). In some embodiments, the heteroaryl group is a 5- to 6-membered aromatic ring system having a cyclic carbon atom and one or more (e.g., 1, 2, 3, or 4) cyclic heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus (“5- to 6-membered heteroaryl”). In some embodiments, the 5- to 6-membered heteroaryl group has one or more (e.g., one, two, or three) cyclic heteroatoms selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus. In some embodiments, the 5- to 6-membered heteroaryl group has one or two cyclic heteroatoms selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus. In some embodiments, the 5- to 6-membered heteroaryl group has one cyclic heteroatom selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus. Unless otherwise specified, each example of a heteroaryl group is independently unsubstituted (“unsubstituted heteroaryl”) or substituted with one or more substituents (“substituted heteroaryl”). In some embodiments, the heteroaryl group is an unsubstituted 5- to 14-membered heteroaryl group. In some embodiments, the heteroaryl group is a substituted 5- to 14-membered heteroaryl group.
[0099] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrole, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetraazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azirzolyl, oxapranyl, and thiaapranyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazole, benzotriazolyl, benzothiophene, isobenzothiophene, benzofuranyl, benzoisofuranyl, benzoimidazolyl, benzoxazolyl, benzoisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl, indolizinyl, and purine. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthidyl, pteridinyl, quinolinyl, isoquinolinyl, cenolinyl, quinoxolinyl, terazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include, but are not limited to, phenidyl, dibenzofuranyl, carbazole, acridineyl, phenthiazinyl, phenoxazinyl, and phenazinyl.
[0100] As used herein, "heterocyclic group" or "heterocycle" refers to a 3- to 14-membered non-aromatic ring system group having a ring carbon atom and one or more (e.g., 1, 2, 3, or 4) ring heteroatoms, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus ("3- to 14-membered heterocyclic group"). In heterocyclic groups containing one or more nitrogen atoms, the bonding point may be a carbon or nitrogen atom, where the valence permits. Heterocyclic groups may be monocyclic ("monocyclic heterocyclic group") or polycyclic (e.g., fused, bridged, or spirocyclic systems, such as bicyclic systems ("bicyclic heterocyclic group") or tricyclic systems ("tricyclic heterocyclic group")). They may be saturated or may contain one or more carbon-carbon double or triple bonds. Heterocyclic polycyclic systems may include one or more heteroatoms in one or two rings. "Heterocyclic group" also includes ring systems in which a heterocyclic ring as defined above is fused with one or more carbocyclic groups, wherein the connection point is on the carbocyclic or heterocyclic ring; or ring systems in which a heterocyclic group as defined above is fused with one or more aryl or heteroaryl groups, wherein the connection point is on the heterocyclic ring. In such cases, the number of ring members continues to indicate the number of ring members in the heterocyclic ring system. Unless otherwise specified, each example of a heterocyclic group is independently unsubstituted ("unsubstituted heterocyclic group") or substituted with one or more substituents ("substituted heterocyclic group"). In some embodiments, the heterocyclic group is an unsubstituted 3- to 14-membered heterocyclic group. In some embodiments, the heterocyclic group is a substituted 3- to 14-membered heterocyclic group.
[0101] In some embodiments, the heterocyclic group is a 5- to 10-membered non-aromatic ring system having a cyclic carbon atom and one or more (e.g., 1, 2, 3, or 4) cyclic heteroatoms, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus (“5- to 10-membered heterocyclic group”). In some embodiments, the heterocyclic group is a 5- to 8-membered non-aromatic ring system having a cyclic carbon atom and one or more (e.g., 1, 2, 3, or 4) cyclic heteroatoms, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus (“5- to 8-membered heterocyclic group”). In some embodiments, the heterocyclic group is a 5- to 6-membered non-aromatic ring system having a cyclic carbon atom and one or more (e.g., 1, 2, 3, or 4) cyclic heteroatoms, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus (“5- to 6-membered heterocyclic group”). In some embodiments, the 5- to 6-membered heterocyclic group has one or more (e.g., one, two, or three) cyclic heteroatoms selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus. In some embodiments, the 5- to 6-membered heterocyclic group has one or two cyclic heteroatoms selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus. In some embodiments, the 5- to 6-membered heterocyclic group has one cyclic heteroatom selected from oxygen, sulfur, nitrogen, boron, silicon, and phosphorus.
[0102] Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to, aziridinyl, epoxyethyl, and cyclothioethyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to, azirrobutyl, oxetyl, and thiobutyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolyl, dihydropyrrolyl, and pyrrolyl-2,5-diketone. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxetyl, oxetyl, and dithiophene. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropiperanyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithiohexyl, and dioxane. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, triazacyclohexyl. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azirheptanyl, oxeheptanyl, and thioheptanyl. Exemplary 8-membered heterocyclic groups containing one heteroatom include, but are not limited to, azirheptanyl, oxeheptanyl, and thioheptanyl. Exemplary bicyclic heterocyclic groups include, but are not limited to, indololinyl, isoindololinyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, tetrahydrobenzothiophenyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthidyl, decahydro-1,8-naphthidyl, octahydropyrrolo[3,2-b]pyrrole, indololinyl, phthalimide, naphthalimide, chromylalkyl, chromenyl, 1H-benzo[e][1,4]diazazolyl, 1,4,5,7-tetrahydropyranolo[3,4-b]pyrrole, 5,6-di Hydrogen-4H-furano[3,2-b]pyrrolithyl, 6,7-dihydro-5H-furano[3,2-b]piperanyl, 5,7-dihydro-4H-thieno[2,3-c]piperanyl, 2,3-dihydro-1H-pyrroli[2,3-b]pyridyl, 2,3-dihydrofurano[2,3-b]pyridyl, 4,5,6,7-tetrahydro-1H-pyrroli-[2,3-b]pyridyl, 4,5,6,7-tetrahydrofurano[3,2-c]pyridyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridyl, 1,2,3,4-tetrahydro-1,6-naphthidyl and similar compounds.
[0103] Heterocyclic alkyl: As used herein, the term “heterocyclic alkyl” is a non-aromatic ring in which at least one atom is a heteroatom, such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus, and the remaining atom is carbon. Heterocyclic alkyl may be substituted or unsubstituted.
[0104] As understood above, in some embodiments, alkyl, alkenyl, alkynyl, acyl, carbocyclic, heterocyclic, aryl, and heteroaryl groups, as defined herein, are optionally substituted. Optional substitution means a substituted or unsubstituted group (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” heteroalkyl, “substituted” or “unsubstituted” heteroalkenyl, “substituted” or “unsubstituted” carbocyclic, “substituted” or “unsubstituted” heterocyclic, “substituted” or “unsubstituted” aryl, or “substituted” or “unsubstituted” heteroaryl). Generally, the term “substituted” means that at least one hydrogen atom present on the group is replaced by a permissible substituent, for example, resulting in a stable compound after substitution. Substituents, for example, in compounds that do not spontaneously undergo transformation through reactions such as rearrangement, cyclization, elimination, or other reactions. Unless otherwise indicated, a “substituted” group has substituents at one or more substituted positions of the group, and when more than one position in any given structure is substituted, the substituents are either the same or different at each position. The term “substituted” is intended to include substitution by all permissible substituents of an organic compound, any substituents described herein that result in the formation of a stable compound. This invention covers any and all such combinations to obtain a stable compound. For the purposes of this invention, heteroatoms (such as nitrogen) may have hydrogen substituents and / or any suitable substituents as described herein that satisfy the heteroatom valence and result in the formation of a stable moiety.
[0105] Exemplary carbon substituents include, but are not limited to, halogens, -CN, -NO2, -N3, -SO2, -SO3H, -OH, and -OR. aa -ON(R) bb )2、-N(R bb )2、-N(R bb )3+X - -N(OR) cc )R bb -SeH, -SeR aa -SH, -SR aa -SSR cc -C(=O)R aa -CO2H, -CHO, -C(OR) cc )2、-CO2R aa -OC(=O)R aa -OCO2R aa -C(=O)N(R) bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3-OSi(R aa )3-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa 、-P(=O)(R aa )2、-OP(=O)(R aa )2、-OP(=O)(OR cc )2、-P(=O)2N(R bb )2、-OP(=O)2N(R bb )2、-P(=O)(NR bb )2、-OP(=O)(NR bb )2、-NRbb P(=O)(OR cc )2、-NR bb P(=O)(NR bb )2、-P(R cc )2、-P(R cc )3、-OP(R cc )2、-OP(R cc )3、-B(R aa 2. -B(OR) cc )2、-BR aa (OR cc C1-C 50 Alkyl, C2-C 50 alkenyl, C2-C 50 alkynyl group, C3-C 14 Carbocyclic group, 3-14 membered heterocyclic group, C6-C 14 Aryl and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently determined by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution; Or two twin hydrogens on a carbon atom via the groups =O, =S, =NN(R) bb )2、=NNR bb C(=O)R aa =NNR bb C(=O)OR aa =NNR bb S(=O)2R aa =NR bb or = NOR cc Displacement;
[0106] R aa Each example is independently selected from C1-C1. 50 Alkyl, C2-C 50 alkenyl, C2-C 50 alkynyl group, C3-C 10 Carbocyclic group, 3-14 membered heterocyclic group, C6-C 14 aryl and 5-14 heteroaryl, or two R aa Groups are joined to form 3-14 membered heterocyclic groups or 5-14 membered heteroaryl rings, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently connected by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;
[0107] R bb Each example is independently selected from hydrogen, -OH, -OR aa ,-N(R cc -CN, -C(=O)R aa-C(=O)N(R) cc )2、-CO2R aa -SO2R aa -C(=NR) cc OR aa -C(=NR) cc )N(R cc )2、-SO2N(R cc )2、-SO2R cc -SO2OR cc -SOR aa -C(=S)N(R) cc )2、-C(=O)SR cc -C(=S)SR cc -P(=O)2R aa -P(=O)(R aa )2、-P(=O)2N(R cc )2、-P(=O)(NR cc 2. C1-C 50 Alkyl, C2-C 50 alkenyl, C2-C 50 alkynyl group, C3-C 10 Carbocyclic group, 3-14 membered heterocyclic group, C6-C 14 aryl and 5-14 heteroaryl, or two R bb The group, together with the heteroatom it is attached to, forms a 3-14 membered heterocyclic group or a 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently defined by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;
[0108] R cc Each example is independently selected from hydrogen, C1-C 50 Alkyl, C2-C 50 alkenyl, C2-C 50 alkynyl group, C3-C 10 Carbocyclic group, 3-14 membered heterocyclic group, C6-C 14 aryl and 5-14 heteroaryl, or two R cc The group, together with the heteroatom it is attached to, forms a 3-14 membered heterocyclic group or a 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently defined by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;
[0109] R dd Each example is independently selected from halogens, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee、-ON(R ff )2、-N(R ff )2、-N(R ff )3+X - 、-N(OR ee )R ff 、-SH、-SR ee 、-SSR ee 、-C(=O)R ee 、-CO2H、-CO2R ee 、-OC(=O)R ee 、-OCO2R ee 、-C(=O)N(R ff )2、-OC(=O)N(R ff )2、-NR ff C(=O)R ee 、-NR ff CO2R ee 、-NR ff C(=O)N(R ff )2、-C(=NR ff )OR ee 、-OC(=NR ff )R ee 、-OC(=NR ff )OR ee 、-C(=NR ff )N(R ff )2、-OC(=NR ff )N(R ff )2、-NR ff C(=NR ff )N(R ff )2、-NR ff SO2R ee 、-SO2N(R ff )2、-SO2R ee 、-SO2OR ee 、-OSO2R ee 、-S(=O)R ee 、-Si(R ee )3、-OSi(R ee )3、-C(=S)N(R ff )2、-C(=O)SR ee 、-C(=S)SR ee 、-SC(=S)SR ee 、-P(=O)2R ee 、-P(=O)(R ee )2、-OP(=O)(R ee )2、-OP(=O)(ORee 2. C1-C 50 Alkyl, C2-C 50 alkenyl, C2-C 50 alkynyl group, C3-C 10 Carbocyclic groups, 3-10 membered heterocyclic groups, C6-C 10 Aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently determined by 0, 1, 2, 3, 4, or 5 R groups. gg Group substitution, or two twin Rs dd Substituents can combine to form =O or =S;
[0110] R ee Each example is independently selected from C1-C1. 50 Alkyl, C2-C 50 alkenyl, C2-C 50 alkynyl group, C3-C 10 carbonyl group, C6-C 10 Aryl, 3-10 membered heterocyclic and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl and heteroaryl group is independently determined by 0, 1, 2, 3, 4 or 5 R groups. gg Group substitution;
[0111] R ff Each example is independently selected from hydrogen, C1-C 50 Alkyl, C2-C 50 alkenyl, C2-C 50 alkynyl group, C3-C 10 Carbocyclic groups, 3-10 membered heterocyclic groups, C6-C 10 aryl and 5-10 heteroaryl, or two R ff The group, together with the heteroatom it is attached to, forms a 3-14 membered heterocyclic group or a 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently defined by 0, 1, 2, 3, 4, or 5 R groups. gg Group substitution; and
[0112] R gg Each example is independently a halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC1-C 50 Alkyl, -ON (C1-C) 50 Alkyl)2, -N(C1-C 50 Alkyl)2, -N(C1-C 50 Alkyl)3+X - -NH(C1-C 50 Alkyl)2+X - -NH2(C1-C 50alkyl)+X - -NH3+X - -N(OC1-C 50 Alkyl) (C1-C 50 Alkyl group, -N(OH) (C1-C 50 Alkyl), -NH(OH), -SH, -SC1-C 50 Alkyl, -SS (C1-C 50 Alkyl), -C(=O)(C1-C 50 Alkyl groups, -CO2H, -CO2 (C1-C) 50 Alkyl), -OC (=O) (C1-C) 50 Alkyl), -OCO2 (C1-C 50 Alkyl groups, -C(=O)NH2, -C(=O)N(C1-C 50 Alkyl)2、-OC(=O)NH(C1-C 50 Alkyl), -NHC(=O)(C1-C 50 Alkyl), -N(C1-C 50 Alkyl)C(=O)(C1-C 50 Alkyl), -NHCO2 (C1-C 50 Alkyl), -NHC(=O)N(C1-C 50 Alkyl)2、-NHC(=O)NH(C1-C 50 Alkyl groups), -NHC(=O)NH2, -C(=NH)O(C1-C 50 Alkyl), -OC (=NH)(C1-C 50 Alkyl), -OC (=NH)OC1-C 50 Alkyl group, -C(=NH)N(C1-C) 50 Alkyl)2、-C(=NH)NH(C1-C 50 Alkyl groups, -C(=NH)NH2, -OC(=NH)N(C1-C 50 Alkyl)2、-OC(NH)NH(C1-C 50 Alkyl groups, -OC(NH)NH2, -NHC(NH)N(C1-C 50 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C1-C 50 Alkyl), -SO2N(C1-C 50 alkyl)2、-SO2NH(C1-C 50 Alkyl groups, -SO2NH2, -SO2(C1-C) 50 Alkyl), -SO2O(C1-C 50Alkyl), -OSO2 (C1-C6 alkyl), -SO (C1-C6 alkyl), -Si (C1-C 50 Alkyl)3, -OSi (C1-C6 alkyl)3, -C(=S)N (C1-C 50 Alkyl)2, C(=S)NH(C1-C 50 Alkyl), C(=S)NH2, -C(=O)S(C1-C6 alkyl), -C(=S)S(C1-C6 alkyl), -SC(=S)S(C1-C6 alkyl), -P(=O)2(C1-C 50 Alkyl group, -P (=O) (C1-C) 50 Alkyl)2、-OP(=O)(C1-C 50 Alkyl)2、-OP(=O)(OC1-C 50 Alkyl)2, C1-C 50 Alkyl, C2-C 50 alkenyl, C2-C 50 alkynyl group, C3-C 10 carbonyl group, C6-C 10 aryl, 3-10 heterocyclic, 5-10 heteroaryl; or two twin R gg Substituents can combine to form =O or =S; where X - It is a relative ion.
[0113] As used herein, the term “halogen” or “halogen” refers to fluorine (fluorinyl, -F), chlorine (chloroyl, -Cl), bromine (bromoyl, -Br) or iodine (iodoyl, -I).
[0114] As used herein, a “relative ion” is a negatively charged group that binds to a positively charged quaternary amine to maintain electronic neutrality. Exemplary relative ions include halide ions (e.g., F). - Cl - ,Br - I - NO3 - ClO4 - OH - H2PO4 - HSO4 - Sulfonate ions (e.g., methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphorsulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonate-5-sulfonate, acetyl-1-sulfonate-2-sulfonate and the like) and carboxylate ions (e.g., acetate, propionate, benzoate, glycerate, lactate, tartrate, glycolate and the like).
[0115] Where the valence allows, the nitrogen atom may be substituted or unsubstituted, and may include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, -OH, and -OR. aa -N(R) cc )2、-CN、-C(=O)R aa -C(=O)N(R) cc )2、-CO2R aa -SO2R aa -C(=NR) bb )R aa -C(=NR) cc OR aa -C(=NR) cc )N(R cc )2、-SO2N(R cc )2、-SO2R cc -SO2OR cc -SOR aa -C(=S)N(R) cc )2、-C(=O)SR cc -C(=S)SR cc -P(=O)2R aa -P(=O)(R aa )2、-P(=O)2N(R cc )2、-P(=O)(NR cc 2. C1-C 50 Alkyl, C2-C 50 alkenyl, C2-C 50 alkynyl group, C3-C 10 Carbocyclic group, 3-14 membered heterocyclic group, C6-C 14 aryl and 5-14 heteroaryl, or two R cc The group, together with the nitrogen atom it is attached to, forms a 3-14 membered heterocyclic group or a 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently defined by 0, 1, 2, 3, 4, or 5 R atoms. dd Group substitution, wherein R aa R bb R cc and R dd As defined above.
[0116] In some embodiments, the substituents present on the nitrogen atom are nitrogen protecting groups (also known as amino protecting groups). Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, which are incorporated herein by reference.
[0117] For example, nitrogen-protecting groups, such as amide groups (e.g., -C(=O)R) aa This includes, but is not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropionamide, pyridinecarboxamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, o-nitrophenoxyacetamide, acetylacetamide, (N'-dithiobenzomethoxyacylamino)acetamide, 3-(p-hydroxyphenyl)propionamide, 3-(o-nitrophenyl)propionamide, 2-methyl-2-(o-nitrophenoxy)propionamide, 2-methyl-2-(o-phenylazophenoxy)propionamide, 4-chlorobutyramide, 3-methyl-3-nitrobutyramide, o-nitrocinnamamide, N-acetylmethionine derivatives, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.
[0118] Nitrogen protecting groups, such as urethane groups (e.g., -C(=O)OR) aaThis includes, but is not limited to, methyl carbamate, ethyl carbamate, 9-fluorenyl methyl carbamate (Fmoc), 9-(2-sulfonyl)fluorenyl methyl carbamate, 9-(2,7-dibromo)fluorenyl methyl carbamate, methyl 2,7-di-tert-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]carbamate (DBD-Tmoc), 4-methoxybenzoyl methyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilyl ethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), and amino... 1,1-Dimethyl-2-haloethyl formate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenyl)ethyl carbamate (Bpoc), 1-(3,5-di-tert-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylformamido)ethyl carbamate, tert-butyl carbamate (BOC), 1-adamantane carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Allo) c) 1-Isopropyl allyl carbamate (Ipaoc), styrene-allyl carbamate (Coc), 4-nitrocinonyl carbamate (Noc), 8-quinoline carbamate, N-hydroxypiperidinyl carbamate, alkyl dithiocarbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitrobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinyl benzyl carbamate (Msz), 9-anthrayl methyl carbamate, diphenyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonyl ethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate [2-(1,3-dithiacyclohexyl)]methyl carbamate (Dmoc), 4-methylthiophene carbamate (Mtpc), 2,4-dimethylthiophene carbamate (Bmpc), 2-phosphonium ethyl carbamate (Peoc), 2-triphenylphosphonium isopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolyl methyl carbamate, 2-(trifluoromethyl)-6-chromone methyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrophenyl carbamate, 3,4-Dimethoxy-6-nitrobenzene, Toluyl (o-nitrophenyl) carbamate, Triamyl carbamate, S-benzyl thiocarbamate, p-cyanobenzoate, Cyclobutyl carbamate, Cyclohexyl carbamate, Cyclopentyl carbamate, Cyclopropyl methyl carbamate, p-decoxybenzyl carbamate, 2,2-dimethoxyvinyl carbamate, o-(N,N-dimethylformamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylformamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, Di(2-pyridyl)methyl carbamate, 2-furanyl methyl carbamate, 2-iodoethyl carbamate, Isoborneol carbamate Isobutyl carbamate, isonicotinic carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(benzoazo)benzyl carbamate, 2,4,6-tri-tert-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.
[0119] Nitrogen protecting groups, such as sulfonamide groups (e.g., -S(=O)2R) aa ), including but not limited to p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilyl ethanesulfonamide (SES), 9-anthracitesulfonamide, 4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzenemethylsulfonamide, trifluoromethylsulfonamide and benzoylmethylsulfonamide.
[0120] Other nitrogen protecting groups include, but are not limited to, phenanthrazinyl-(10)-acyl derivatives, N'-p-toluenesulfonylaminoacyl derivatives, N'-phenylaminothioacyl derivatives, N-benzoylphenylalanyl derivatives, N-acetylmethionine derivatives, 4,5-diphenyl-3-oxazoline-2-one, N-phthalimide, N-dithiosuccinimide (Dts), N-2,3-diphenylcis-butene diimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisiloxane adduct (STABASE), and 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexane-2 - Ketones, 5-substituted 1,3-diphenylmethyl-1,3,5-triazacyclohexane-2-one, 1-substituted 3,5-dinitro-4-pyridinone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrololin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzocycloheptanamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluoreneamine (PhF), N-2,7-diphenylmethylamine, N ... Chloro-9-fluorenylmethyleneamine, N-ferrocene-methylamino (Fcm), N-2-pyridinemethylamino N'-oxide, N-1,1-dimethylthiomethyleneamine, N-benzylmethyleneamine, N-p-methoxybenzylmethyleneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)trimethylmethyl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, N,N'-isopropylidene diamine, N-p-nitrobenzylmethyleneamine, N-salinomylamine, N-5-chlorosalinomylamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine N-borane derivatives, N-diphenylboronic acid derivatives, N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelating agents, N-zinc chelating agents, N-nitroamines, N-nitrosoamines, amine N-oxides, diphenylphosphamide (Dpp), dimethylthiophosphamide (Mpt), diphenylthiophosphamide (Ppt), dialkyl aminophosphate, diphenylaminophosphate, diphenylaminophosphate, benzenesulfinamide, o-nitrobenzenesulfinamide (Nps), 2,4-dinitrobenzenesulfinamide, pentachlorobenzenesulfinamide, 2-nitro-4-methoxybenzenesulfinamide, triphenylmethylsulfinamide, and 3-nitropyridinesulfinamide (Npys).
[0121] In some embodiments, the substituents present on the oxygen atom are oxygen protecting groups (also known as hydroxy protecting groups). Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, which are incorporated herein by reference.
[0122] Exemplary oxygen protecting groups include, but are not limited to, methyl, methoxymethyl (MOM), methylthiomethyl (MTM), tert-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), o-methoxyphenol methyl (GUM), tert-butoxymethyl, 4-pentenoxymethyl (POM), silanoxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), and tetrahydropiperanyl (THP). 3-Bromotetrahydropiperanyl, tetrahydrothiopiperanyl, 1-methoxycyclohexyl, 4-methoxytetrahydropiperanyl (MTHP), 4-methoxytetrahydrothiopiperanyl, 4-methoxytetrahydrothiopiperanyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxane-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanolbenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzoxyethyl 1-Methyl-1-benzoxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenoethyl)ethyl, tert-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-pyridylmethyl, 4-pyridylmethyl, 3-methyl-2-pyridylmethyl N-oxo ion, diphenylmethyl, p,p'-dinitrodiphenylmethyl, 5-dibenzocycloheptanyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxybenzyl Diphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromobenzoylmethyloxyphenyl)diphenylmethyl, 4,4',4”-tris(4,5-dichlorophthaliminophenyl)methyl, 4,4',4”-tris(inulinolyloxyphenyl)methyl, 4,4',4”-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4',4”-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenemethyl, 9-anthrayl, 9-(9-phenyl)tonyl, 9-(9-phenyl-10-oxo)anthrayl, 1,3-benzodithiofuran-2-yl, benzisothiazolyl S,S-dioxane ion group, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethyltrihexylsilyl, tert-butyldimethylsilyl (TBDMS), tert-butylbiphenylsilyl (TBDPS), triphenylmethylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), tert-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p- Chlorophenoxyacetic acid ester, 3-phenylpropionate, 4-oxovalerate (acetylpropionate), 4,4-(ethylidene dithio)valerate (acetylpropionyl dithioacetal), pteropenoate, adamantate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (trimethylbenzene ester), methyl carbonate, 9-fluorenyl carbonate (Fmoc), ethyl carbonate, 2,2,2-trichloroethyl carbonate (Troc), ethyl carbonate (TMSEC), ethyl carbonate (Psec), ethyl carbonate (Peoc), carbonate Alkyl isobutyl ester, alkyl ethylene carbonate, alkyl allyl carbonate, alkyl p-nitrobenzene carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzene carbonate, alkyl 3,4-dimethoxybenzene carbonate, alkyl o-nitrobenzene carbonate, alkyl p-nitrobenzene carbonate, thioalkyl carbonate S-benzene, 4-ethoxy-1-naphthyl carbonate, dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylvalerate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methyl Phenoxyacetic acid esters, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetic acid esters, 2,4-bis(1,1-dimethylpropyl)phenoxyacetic acid esters, dichlorophenylacetic acid esters, isobutyrate esters, monosuccinate esters, (E)-2-methyl-2-butenoate esters, o-(methoxyyl)benzoate esters, α-naphthyl esters, nitrate esters, N,N,N',N'-tetramethyldiaminophosphate alkyl esters, N-phenylcarbamate alkyl esters, borate esters, dimethylphosphinothionyl esters, 2,4-dinitrophenylsulfinic acid alkyl esters, sulfate esters, methanesulfonate / mesylate esters, benzylmethylsulfonate esters, and toluenesulfonate esters (Ts).
[0123] In some embodiments, the substituents present on the sulfur atom are sulfur protecting groups (also known as thiol protecting groups). Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, which are incorporated herein by reference.
[0124] Exemplary sulfur protecting groups include, but are not limited to, alkyl, benzyl, p-methoxybenzyl, 2,4,6-trimethylbenzyl, 2,4,6-trimethoxybenzyl, o-hydroxybenzyl, p-hydroxybenzyl, o-acetoxybenzyl, p-acetoxybenzyl, p-nitrobenzyl, 4-pyridylmethyl, 2-quinolinylmethyl, 2-pyridylmethyl N-oxo ion, 9-anthraylmethyl, 9-fluorenylmethyl, tonyl, fluorenylmethyl, diphenylmethyl, bis(4-methoxyphenyl)methyl, 5-dibenzocycloheptanyl, triphenylmethyl, diphenyl-4-pyridylmethyl, phenyl, 2,4-dinitrophenyl, tert-butyl, 1-adamantyl, methoxymethyl (MOM), isobutoxymethyl, benzyloxymethyl, 2-tetrahydropiperanyl, benzylthiomethyl, phenylthiomethyl, tetrahydrothiazolyl, acetamylmethyl, trimethylacetamylmethyl, benzamidemethyl, allyloxycarbonylaminomethyl , phenylacetamidomethyl, phthalimidemethyl, acetylmethyl, carboxymethyl, cyanomethyl, (2-nitro-1-phenyl)ethyl, 2-(2,4-dinitrophenyl)ethyl, 2-cyanoethyl, 2-(trimethylsilyl)ethyl, 2,2-bis(ethoxycarbonyl)ethyl, (1-m-nitrophenyl-2-benzoyl)ethyl (othyl), 2-benzenesulfonylethyl, 2-(4-methylbenzenesulfonyl)-2-methylprop- 2-yl, acetyl, benzoyl, trifluoroacetyl, N-[[(p-biphenyl)isopropoxy]carbonyl]-N-methyl]-γ-aminothiobutyrate, 2,2,2-trichloroethoxycarbonyl, tert-butoxycarbonyl, benzoxycarbonyl, p-methoxybenzoxycarbonyl, N-ethyl, N-methoxymethyl, sulfonate, sulfinyl thiocarbonate, 3-nitro-2-pyridinesulfinyl thioether, oxathiolone. Compounds of the present invention
[0125] Liposome-based mediators are considered attractive carriers for therapeutics and require continued development. While liposome-based mediators containing certain lipid components have shown promising results regarding encapsulation, stability, and site localization, there remains a significant need to improve liposome-based delivery systems. For example, significant drawbacks of liposome delivery systems relate to the construction of liposomes with sufficient cell culture or in vivo stability to reach desired target cells and / or intracellular compartments, and the ability of such liposome delivery systems to effectively release their encapsulating material to these target cells.
[0126] In particular, there remains a need for improved lipid compounds that exhibit, for example, improved pharmacokinetic properties and the ability to deliver macromolecules (such as nucleic acids) to a wide range of cell types and tissues with enhanced efficiency. Importantly, there is also a particular need for novel lipid compounds characterized, for example, reduced toxicity and the ability to efficiently deliver encapsulated nucleic acids and polynucleotides to targeted cells, tissues, and organs.
[0127] This article describes cationic lipid compounds for improving the in vivo delivery of therapeutic agents (such as nucleic acids). In particular, the cationic lipids described herein may optionally be used with other lipids to formulate lipid-based nanoparticles (e.g., liposomes) for encapsulating therapeutic agents (such as nucleic acids) (e.g., DNA, siRNA, mRNA, and / or microRNA) for therapeutic purposes.
[0128] In embodiments, the compounds of the present invention as described herein may provide one or more desired features or properties. That is, in some embodiments, the compounds of the present invention as described herein may be characterized by having one or more properties that provide advantages over other similarly classified lipids. For example, the compounds disclosed herein may allow control and adjustment of the properties of liposome compositions (e.g., lipid nanoparticles) in which they are components. In particular, the compounds disclosed herein may be characterized by enhanced transfection efficiency and their ability to induce specific biological outcomes. Such outcomes may include, for example, enhanced cellular uptake, endosome / lysosome disruption, and / or promotion of intracellular release of encapsulating materials (e.g., polynucleotides). Additionally, the compounds disclosed herein have favorable pharmacokinetic properties, biodistribution, and efficiency (e.g., due to the different dissociation rates of the polymer groups used).
[0129] This application confirms that the cationic lipids of the present invention can be easily synthesized from readily available starting materials, and also have unexpectedly high encapsulation efficiency.
[0130] Furthermore, the cationic lipids of the present invention have cleavable groups, such as ester groups and disulfide bonds. These cleavable groups (e.g., esters and disulfide bonds) are expected to improve biodegradability and thus contribute to their favorable toxicity profile.
[0131] This document provides compounds that are cationic lipids. For example, the cationic lipids of the present invention include compounds having a structure according to formula (I′z): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, 5, and 6; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
[0132] For example, the cationic lipids of the present invention include compounds having a structure according to formula (II'z): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R is selected independently from: (i) Among them, each R 1Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, 5, and 6; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0133] For example, the cationic lipids of the present invention include compounds having a structure according to formula (III'z): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, 5, and 6; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
[0134] For example, the cationic lipids of the present invention include compounds having the structure according to formula (IV'z): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, 5, and 6; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0135] For example, the cationic lipids of the present invention include compounds having a structure according to formula (V'z): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, 5, and 6; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
[0136] For example, the cationic lipids of the present invention include compounds having the structure according to formula (VI'z): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, 5, and 6; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0137] For example, the cationic lipids of the present invention include compounds having a structure according to formula (VII'z): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, 5, and 6; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0138] For example, the cationic lipids of the present invention include compounds having a structure according to formula (Iz): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; and Each 'a' is independently selected from 2, 3, 4, 5, and 6.
[0139] For example, the cationic lipids of the present invention include compounds having a structure according to formula (IIz): Or its pharmaceutically acceptable salt, wherein: A1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R is selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, 5, and 6; and c is 3 or 4.
[0140] For example, the cationic lipids of the present invention include compounds having a structure according to formula (IIIz): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, 5, and 6.
[0141] For example, the cationic lipids of the present invention include compounds having a structure according to formula (IVz): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, 5, and 6; and c is 3 or 4.
[0142] For example, the cationic lipids of the present invention include compounds having a structure according to formula (Vz): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, 5, and 6.
[0143] For example, the cationic lipids of the present invention include compounds having a structure according to formula (VIz): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and RD Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, 5, and 6; and c is 3 or 4.
[0144] For example, the cationic lipids of the present invention include compounds having a structure according to formula (VIIz): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, 5, and 6; and c is 3 or 4.
[0145] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (Iaz): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 R 2 And a is as defined for equation (Iz).
[0146] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIaz): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 R 2 a and c are as defined with respect to equation (IIz).
[0147] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIIaz): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 and a as defined for equation (IIIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D(Not all are the same).
[0148] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IVaz): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 R 2 a and c are as defined with respect to equation (IVz).
[0149] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (Vaz): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 and a is as defined for equation (Vz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0150] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VIaz): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 a and c are as defined with respect to equation (VIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0151] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VIIaz): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 a and c are as defined with respect to equation (VIIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0152] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIbz): Or a pharmaceutically acceptable salt thereof, wherein R 2 a and c are as defined with respect to equation (IIz).
[0153] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIIbz): Or a pharmaceutically acceptable salt thereof, wherein a is as defined for formula (IIIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0154] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VIbz): Or a pharmaceutically acceptable salt thereof, wherein a and c are as defined for formula (VIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0155] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (Icz): Or a pharmaceutically acceptable salt thereof, wherein R 2 And a is as defined for equation (Iz).
[0156] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIcz): Or a pharmaceutically acceptable salt thereof, wherein R 2 a and c are as defined with respect to equation (IIz).
[0157] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIIcz): Or a pharmaceutically acceptable salt thereof, wherein a is as defined for formula (IIIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0158] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IVcz): Or a pharmaceutically acceptable salt thereof, wherein R 2 a and c are as defined with respect to equation (IVz).
[0159] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (Vcz): Or a pharmaceutically acceptable salt thereof, wherein a is as defined for formula (Vz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0160] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VIcz): Or a pharmaceutically acceptable salt thereof, wherein a and c are as defined for formula (VIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0161] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VIIcz): Or a pharmaceutically acceptable salt thereof, wherein a and c are as defined with respect to formula (VIIz), and each R2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0162] For example, the cationic lipids of the present invention include compounds having a structure according to formula (I′): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
[0163] For example, the cationic lipids of the present invention include compounds having a structure according to formula (II'): Or its pharmaceutically acceptable salt, wherein: A1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R is selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0164] For example, the cationic lipids of the present invention include compounds having a structure according to formula (III'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
[0165] For example, the cationic lipids of the present invention include compounds having the structure according to formula (IV'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0166] For example, the cationic lipids of the present invention include compounds having the structure according to formula (V'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
[0167] For example, the cationic lipids of the present invention include compounds having the structure according to formula (VI'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0168] For example, the cationic lipids of the present invention include compounds having a structure according to formula (VII'): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (i) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (ii) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; Each b is independently selected from 2, 3, 4, 5, 6, and 7; and c is 3 or 4.
[0169] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (I): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; and Each 'a' is independently selected from 2, 3, 4, and 5.
[0170] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (II): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R is selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; and c is 3 or 4.
[0171] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (III): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R DSelected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5.
[0172] In embodiments, the cationic lipids of the present invention comprise compounds having the structure according to formula (IV): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R is selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; Each 'a' is independently selected from 2, 3, 4, and 5; and c is 3 or 4.
[0173] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (V): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B R C and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5.
[0174] In embodiments, the cationic lipids of the present invention comprise compounds having the structure according to formula (VI): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; Each R A R B R C and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; and c is 3 or 4.
[0175] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VII): Or its pharmaceutically acceptable salt, wherein: A 1 Selected from and -SS-, where the left side of each delineated structure is adjacent to -(CH2). a - Combination; Z 1 Selected from and -SS-, where the right side of each delineated structure is adjacent to -(CH2). a - Combination; A 1 and Z 1 different; Each R A R B RC and R D Selected independently from: (iii) Among them, each R 1 Independently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, optionally substituted alkynyl groups, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl groups, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl groups; and (iv) Among them, each R 2 Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups; R A R B R C and R D At least one of them is different (i.e., R) A R B R C and R D (Not all are the same); Each 'a' is independently selected from 2, 3, 4, and 5; and c is 3 or 4.
[0176] In embodiments, the cationic lipids of the present invention comprise compounds having the structure according to formula (Ia): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 R 2 and a is as defined for equation (I).
[0177] In embodiments, the cationic lipids of the present invention comprise compounds having the structure according to formula (IIa): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 R 2 a and c are as defined with respect to equation (II).
[0178] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIIa): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 and a as defined for equation (III), and each R 2A R 2B R2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0179] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IVa): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 R 2 a and c are as defined with respect to equation (IV).
[0180] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (Va): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 and a is as defined for equation (V), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0181] In embodiments, the cationic lipids of the present invention comprise compounds having the structure according to formula (VIa): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 a and c are as defined with respect to equation (VI), and each R 2A R 2B R 2C and R 2DIndependently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0182] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VIIa): Or a pharmaceutically acceptable salt thereof, wherein A 1 Z 1 a and c are as defined with respect to equation (VII), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0183] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIb): Or a pharmaceutically acceptable salt thereof, wherein R 2 a and c are as defined with respect to equation (II).
[0184] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIIb): Or a pharmaceutically acceptable salt thereof, wherein a is as defined for formula (III), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0185] In embodiments, the cationic lipids of the present invention comprise compounds having the structure according to formula (VIb): Or a pharmaceutically acceptable salt thereof, wherein a and c are as defined for formula (VI), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (All parts are the same).
[0186] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (Ic): Or a pharmaceutically acceptable salt thereof, wherein R 2 and a is as defined for equation (I).
[0187] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIc): Or a pharmaceutically acceptable salt thereof, wherein R 2 a and c are as defined with respect to equation (II).
[0188] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIIc): Or a pharmaceutically acceptable salt thereof, wherein a is as defined for formula (III), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0189] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IVc): Or a pharmaceutically acceptable salt thereof, wherein R 2 a and c are as defined with respect to equation (IV).
[0190] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (Vc): Or a pharmaceutically acceptable salt thereof, wherein a is as defined for formula (V), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (All parts are the same).
[0191] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VIc): Or a pharmaceutically acceptable salt thereof, wherein a and c are as defined for formula (VI), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R2D (All parts are the same).
[0192] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VIIc): Or a pharmaceutically acceptable salt thereof, wherein a and c are as defined with respect to formula (VII), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0193] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (Id): Or a pharmaceutically acceptable salt thereof, wherein each of a and R 2 As defined in equation (I) or equation (Iz).
[0194] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IId): Or a pharmaceutically acceptable salt thereof, wherein each of a, c, and R 2 As defined in equation (II) or equation (IIz).
[0195] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IIId): Or a pharmaceutically acceptable salt thereof, wherein each a is as defined in formula (III) or formula (IIIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2DAt least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0196] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (IVd): Or a pharmaceutically acceptable salt thereof, wherein each of a, c, and R 2 As defined in equation (IV) or equation (IVz).
[0197] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (Vd): Or a pharmaceutically acceptable salt thereof, wherein each a is as defined in formula (V) or formula (Vz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0198] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VId): Or a pharmaceutically acceptable salt thereof, wherein each a and c is as defined in formula (VI) or formula (VIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0199] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (VIId): Or a pharmaceutically acceptable salt thereof, wherein each a and c is as defined in formula (VII) or formula (VIIz), and each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl groups, wherein R 2A R 2B R 2C and R 2D At least one of them is different (i.e., R) 2A R 2B R 2C and R 2D (Not all are the same).
[0200] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (I'a): Or its pharmaceutically acceptable salt, wherein each A 1 Z 1 a, b, R 1 and R 2 As defined in equation (I') or equation (I'z), any A can be chosen. 1 for The left side of the structure is depicted in relation to -(CH2). a - Combined, and Z 1 It is -SS-.
[0201] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (II'a): Or its pharmaceutically acceptable salt, wherein each A 1 Z 1 a, b, c, R 1 and R 2 As defined in equation (II') or equation (II'z), any A can be chosen. 1 for The left side of the structure is depicted in relation to -(CH2). a - Combined, and Z 1 It is -SS-.
[0202] In embodiments, the cationic lipids of the present invention comprise compounds having a structure according to formula (III'a): Or its pharmaceutically acceptable salt, wherein each A 1 Z 1 a, b and R 1 As defined in equation (III') or equation (III'z), and each R 2A and R 2B Independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl, wherein A is optionally selected from... 1 for The left side of the structure is depicted in relation to -(CH2). a - Combined, and Z 1 It is -SS-.
[0203] In this invention (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a) In the embodiments of (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is independently selected from 2, 3, and 4.
[0204] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a) are used. In the embodiments of (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz) or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is independently selected from 3 and 4.
[0205] In this invention (for example, a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'), (II'), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIc), or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'), (II'), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VId), (VIId), (I'a), (II'), (IIc), (IIIc), (IVc), (Vc), (VId), (VIId), (I'a), (IIc ... In the embodiments of (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is different.
[0206] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (III'a) In embodiments of (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz) or (VIIcz), or a pharmaceutically acceptable salt thereof), the value of a on the left side of the descriptive formula is less than the value of a on the right side of the descriptive formula.
[0207] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (III'a) In the embodiments of (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), the value of a on the left side of the descriptive formula is 3, and the value of a on the right side of the descriptive formula is 4.
[0208] In embodiments of the present invention (e.g., formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof), the value of a on the left side of the descriptive formula is 3, and the value of a on the right side of the descriptive formula is 6.
[0209] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'), (II'), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), ... (VIIc), (I'a), (II'), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), In the embodiments of (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz) or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is the same.
[0210] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') In the embodiments of (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is 3.
[0211] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc), or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), c is 3.
[0212] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc) or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), c is 4.
[0213] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc), or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), c is 3, the value of a on the left side of the descriptive formula is 3, and the value of a on the right side of the descriptive formula is 4.
[0214] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc) or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), c is 4, the value of a on the left side of the descriptive formula is 3, and the value of a on the right side of the descriptive formula is 4.
[0215] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') In the embodiments of I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl groups. In embodiments of the invention, R 2 Or each R 2A R 2B R2C and R 2D Independently selected from arbitrarily substituted C5-C 50 Alkyl group. In any of the above embodiments, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 40 Alkyl group. In any of the above embodiments, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 30 Alkyl group. In any of the above embodiments, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 25 Alkyl group. In any of the above embodiments, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 20 alkyl.
[0216] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') In the embodiments of I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from C8H 17 C 10 H 21 C 12 H 25 C 14 H 29 C 16 H 33 C 16 H 31 C 16 H 29 and C 16 H 27 .
[0217] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'), (II'), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), ... (VIIc), (I'a), (II'), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), In some embodiments of (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, R 2 Or each R 2A R 2B R 2C and R 2D The substituted alkyl group is optional. In some embodiments, the optionally present substituted alkyl group is -OC(=O)R. aa Substituted alkyl groups, wherein each R aa The alkyl group is independently selected from optionally substituted alkyl groups. In some embodiments, the optionally present substituted alkyl group is substituted with -OC(=O)R. aa Replacement C 1-20 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is alkyl-OC(=O)R. aa Replacement C 1-10 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is alkyl-OC(=O)R. aa Replacement C 1-5 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 alkyl.
[0218] In this invention (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a) In some embodiments of (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, R 2 Or each R 2A R 2B R 2C and R 2D The substituted alkyl group is optional. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Substituted alkyl groups, wherein each R aa The alkyl group is independently selected from optionally substituted alkyl groups. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Replacement C 1-20 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Replacement C 1-10 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Replacement C 1-5 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 alkyl.
[0219] In any of the above implementation schemes, R aa Independently selected from arbitrarily substituted C1-C 40 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 30 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 25 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 20 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 15 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 10 Alkyl group. In any of the above embodiments, R aa Independently selected from optionally substituted C2-C8 alkyl groups. In any of the above embodiments, R aa Independently selected from optionally substituted C3-C7 alkyl groups.
[0220] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IVa), (IIb), (Ic), (IIc) or (IVc), or b) formula (Id), (IId), (IVd), (I'a), (II'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IVaz), (IIbz), (Icz), (IIcz) or (IVcz), or pharmaceutically acceptable salts thereof), each R 2 same.
[0221] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B Same, and R 2C and R 2D same.
[0222] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C Same, and R 2B and R 2D same.
[0223] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') In the embodiments of I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each R 2 or R 2A R 2B R 2C and R 2D At least one of them is C 10 H 21 .
[0224] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (III'a), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B C 10 H 21 .
[0225] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2C and R 2D C 10 H 21 .
[0226] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (III'a), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B C 16 H 31 .
[0227] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2C and R 2D C 16 H 31 .
[0228] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B C 10 H 21 And R 2C and R 2D C 16 H 31 .
[0229] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B C 16 H 31 And R 2C and R 2D C 10 H 21 .
[0230] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C for
[0231] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2B and R 2D for
[0232] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C C 16 H 31 .
[0233] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2B and R 2D C 16 H 31 .
[0234] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C for And R 2B and R 2D C 16 H 31 .
[0235] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C C 16 H 31 And R 2B and R 2D for
[0236] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B The alkyl group is optionally substituted, and R 2C and R 2D The substituted alkenyl group is optional.
[0237] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B The alkenyl group is optionally substituted, and R 2C and R 2D The alkyl group is optionally substituted.
[0238] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C For -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl, and R 2B and R 2D The substituted alkenyl group is optional.
[0239] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C The alkenyl group is optionally substituted, and R 2B and R 2D -Optionally substituted alkyl-(C=O)-O-Optionally substituted alkyl.
[0240] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (III'a), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), each R 2A R 2B R 2C and R 2D Selected independently from: and
[0241] In the present invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), and formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'), (II'), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), ... (VIIc), (I'a), (II'), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIIc), (I'a), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc), (IIc In the embodiments of (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each R 2 or R 2A R 2B R 2C and R 2D At least one of them is via -OC(=O)R aa Replacement C 1-20 Alkyl groups, wherein each R aaIndependently selected from arbitrarily substituted C1-C 20 alkyl.
[0242] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') In the embodiments of I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each R 2 or R 2A R 2B R 2C and R 2D At least one of them is -CO2R aa Replacement C 1-20 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 20 alkyl.
[0243] In this invention (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (I') In the embodiments of II'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is independently selected from 2, 3, and 4, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl groups. In any of the above embodiments, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 50 Alkyl group. In any of the above embodiments, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 40 Alkyl group. In any of the above embodiments, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 30 Alkyl group. In any of the above embodiments, R 2 Or each R 2A R2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 25 Alkyl group. In any of the above embodiments, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 20 alkyl.
[0244] In this invention (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (I') In the embodiments of II'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is independently selected from 2, 3, and 4, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl groups, wherein the optionally substituted alkyl group is substituted with -OC(=O)R aa Substituted alkyl groups, wherein each R aa The alkyl group is independently selected from optionally substituted alkyl groups. In some embodiments, the optionally present substituted alkyl group is substituted with -OC(=O)R. aa Replacement C 1-20 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50Alkyl group. In some embodiments, the optionally present substituted alkyl group is alkyl-OC(=O)R. aa Replacement C 1-10 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is alkyl-OC(=O)R. aa Replacement C 1-5 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 alkyl.
[0245] In this invention (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (I') In the embodiments of II'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is independently selected from 2, 3, and 4, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from optionally substituted alkyl groups, wherein the optionally substituted alkyl group is -CO2R aa Substituted alkyl groups, wherein each R aa The alkyl group is independently selected from optionally substituted alkyl groups. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Replacement C 1-20 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Replacement C 1-10 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Replacement C 1-5 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 alkyl.
[0246] In any of the above implementation schemes, R aa Independently selected from arbitrarily substituted C1-C 40 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 30 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 25 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 20 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 15 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 10 Alkyl group. In any of the above embodiments, R aa Independently selected from optionally substituted C2-C8 alkyl groups. In any of the above embodiments, R aa Independently selected from optionally substituted C3-C7 alkyl groups.
[0247] In this invention (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (I') In the embodiments of II'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is independently selected from 2, 3, and 4, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from C8H 17 C 10 H 21 C 12 H 25 C 14 H 29 C 16 H 33 C 16 H 31 C 16 H 29 and C 16 H 27 .
[0248] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc) or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), each a is independently selected from 3 and 4, c is 3, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from C8H 17 C 10 H 21 C 12 H 25 C 14 H 29 C 16 H 33 C 16 H 31 C 16 H 29 and C 16 H 27 .
[0249] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc) or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz) or (VIIcz), or a pharmaceutically acceptable salt thereof), each a is independently selected from 3 and 4, c is 4, and R 2 Or each R 2A R 2BR 2C and R 2D Independently selected from C8H 17 C 10 H 21 C 12 H 25 C 14 H 29 C 16 H 33 C 16 H 31 C 16 H 29 and C 16 H 27 .
[0250] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc) or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), the value of a on the left side of the descriptive formula is 3, and the value of a on the right side of the descriptive formula is 4, c is 3, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from C8H 17 C 10 H 21 C 12 H 25 C 14 H 29 C 16 H 33 C 16 H 31 C 16 H 29 and C 16 H 27 .
[0251] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc) or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), the value of a on the left side of the descriptive formula is 3, and the value of a on the right side of the descriptive formula is 4, c is 4, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from C8H 17 C 10 H 21 C 12 H 25 C 14 H 29 C 16 H 33 C 16 H 31 C 16 H 29 and C 16 H 27 .
[0252] In the present invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a) In the embodiments of (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is 3, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from C8H 17 C 10 H 21 C 12 H 25 C 14 H 29 C 16 H 33 C 16 H 31 C 16 H 29 and C 16 H 27 .
[0253] In the present invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a) In the embodiments of (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is 3, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from substituted alkyl groups that are optionally present, wherein the optionally substituted alkyl group is substituted with -OC(=O)R. aa Substituted alkyl groups, wherein each R aa The alkyl group is independently selected from optionally substituted alkyl groups. In some embodiments, the optionally present substituted alkyl group is substituted with -OC(=O)R. aa Replacement C 1-20 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is alkyl-OC(=O)R. aa Replacement C 1-10 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is alkyl-OC(=O)R. aa Replacement C 1-5 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 alkyl.
[0254] In the present invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a) In the embodiments of (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (Ivz), (Vz), (Viz), (VIIz), (Iaz), (Iiaz), (IIIaz), (Ivaz), (Vaz), (Viaz), (VIIaz), (Iibz), (IIIbz), (Vibz), (Icz), (Iicz), (IIIcz), (Ivcz), (Vcz), (Vicz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is 3, and R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from substituted alkyl groups that are optionally present, wherein the optionally substituted alkyl group is -CO2R aa Substituted alkyl groups, wherein each R aa The alkyl group is independently selected from optionally substituted alkyl groups. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Replacement C 1-20 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Replacement C 1-10 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 Alkyl group. In some embodiments, the optionally present substituted alkyl group is -CO2R. aa Replacement C 1-5 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 50 alkyl.
[0255] In any of the above implementation schemes, R aa Independently selected from arbitrarily substituted C1-C 40 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 30 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 25 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 20 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 15 Alkyl group. In any of the above embodiments, R aa Independently selected from arbitrarily substituted C1-C 10 Alkyl group. In any of the above embodiments, R aa Independently selected from optionally substituted C2-C8 alkyl groups. In any of the above embodiments, R aa Independently selected from optionally substituted C3-C7 alkyl groups.
[0256] In embodiments of the present invention (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IVa), (IIb), (Ic), (IIc) or (IVc), or b) formulas (Id), (Iid), (Ivd), (I'a), (II'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IVaz), (IIbz), (Icz), (IIcz) or (IVcz), or pharmaceutically acceptable salts thereof), each a is the same, and each R 2 same.
[0257] In the present invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a) In the embodiments of (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is 3, and each R 2 or R 2A R 2B R 2C and R 2D At least one of them is C 10 H 21 .
[0258] In the present invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a) In the embodiments of (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is 3, and each R 2 or R 2A R 2B R 2C and R 2D At least one of them is via -OC(=O)R aa Replacement C 1-20 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 20 alkyl.
[0259] In the present invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a) In the embodiments of (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is 3, and each R 2 or R 2A R 2B R 2C and R 2D At least one of them is -CO2R aa Replacement of C 1-20 Alkyl groups, wherein each R aa Independently selected from arbitrarily substituted C1-C 20 alkyl.
[0260] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0261] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0262] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0263] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0264] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0265] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0266] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0267] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0268] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0269] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0270] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0271] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0272] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0273] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0274] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0275] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0276] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0277] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0278] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0279] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0280] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0281] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0282] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0283] In the embodiments, the cationic lipids of the present invention are compounds having the following structures: Or its pharmaceutically acceptable salt.
[0284] In this invention, for example, formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (VIIc), or (b) formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (VIIc), (I'a), (II'a), (VIIc) In the embodiments of III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is independently selected from 2, 3, and 4.
[0285] In this invention (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a) In the embodiments of (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is independently selected from 3 and 4.
[0286] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') In the embodiments of (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is different.
[0287] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (III'a) are used. In embodiments of (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), the value of a on the left side of the descriptive formula is less than the value of a on the right side of the descriptive formula.
[0288] In this invention (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II'a), (III'a), (... In embodiments of (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), the value of a on the left side of the descriptive formula is 3, and the value of a on the right side of the descriptive formula is 4.
[0289] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') In the embodiments of (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is the same.
[0290] In this invention, for example, formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') In the embodiments of (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof, each a is 3.
[0291] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is independently selected from 2, 3, 4, 5, 6, and 7.
[0292] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is the same.
[0293] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI') or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is 3.
[0294] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is 7.
[0295] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc) or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), c is 3.
[0296] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc) or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), c is 4.
[0297] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc), or (VIIc), or b) formula (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), c is 3, the value of a on the left side of the descriptive formula is 3, and the value of a on the right side of the descriptive formula is 4.
[0298] In embodiments of the present invention (e.g., a) formula (II'), (IV'), (VI'), (VII'), (II), (IV), (VI), (VII), (IIa), (IVa), (VIa), (VIIa), (IIb), (VIb), (IIc), (IVc), (VIc) or (VIIc) (IId), (IVd), (VId), (VIId), (II'a), (II'z), (IV'z), (VI'z), (VII'z), (IIz), (IVz), (VIz), (VIIz), (IIaz), (IVaz), (VIaz), (VIIaz), (IIbz), (VIbz), (IIcz), (IVcz), (VIcz), or (VIIcz), or (VIIcz), or pharmaceutically acceptable salts thereof), c is 4, the value of a on the left side of the descriptive formula is 3, and the value of a on the right side of the descriptive formula is 4.
[0299] In embodiments of the present invention (e.g., a) formula (III'), (V'), (VI'), (VII'), (III), (V), (VI), or (VII), or b) formula (III'z), (V'z), (VI'z), (VII'z), (IIIz), (Vz), (VIz), or (VIIz), or a pharmaceutically acceptable salt thereof), R A and R B Same, and R C and R D same.
[0300] In embodiments of the present invention (e.g., a) formula (III'), (V'), (VI'), (VII'), (III), (V), (VI), or (VII), or b) formula (III'z), (V'z), (VI'z), (VII'z), (IIIz), (Vz), (VIz), or (VIIz), or a pharmaceutically acceptable salt thereof), R A and R C Same, and R B and R D same.
[0301] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or a pharmaceutically acceptable salt thereof), R 1 Independently selected from optionally substituted alkyl groups. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 50 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 40 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 30 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 25 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 20 alkyl.
[0302] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or a pharmaceutically acceptable salt thereof), each R 1 same.
[0303] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or a pharmaceutically acceptable salt thereof), each R 1 For optional substituted C5-C 20 alkyl.
[0304] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each a is independently selected from 2, 3, and 4, each b is independently selected from 2, 3, 4, 5, 6, and 7, and R 1 Independently selected from optionally substituted alkyl groups. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 50 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 40 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 30 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 25Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 20 alkyl.
[0305] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each a is 3, each b is independently selected from 2, 3, 4, 5, 6, and 7, and R 1 Independently selected from optionally substituted alkyl groups. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 50 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 40 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 30 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 25 Alkyl group. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 20 alkyl.
[0306] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each a is 3, each b is independently selected from 2, 3, 4, 5, 6, and 7, and each R 1 For optional substituted C5-C 20 alkyl.
[0307] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each a is 3, each b is 3, and each R1 For optional substituted C5-C 20 alkyl.
[0308] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (V)z, (VIz) or (VIIz), or a pharmaceutically acceptable salt thereof), R 1 Independently selected from optionally substituted alkenyl groups. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 50 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 40 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 30 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 25 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 20 Alkenyl group.
[0309] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (V), (VIz) or (VIIz), or a pharmaceutically acceptable salt thereof), each R 1 same.
[0310] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or a pharmaceutically acceptable salt thereof), each R 1 For optional substituted C5-C 20 Alkenyl group.
[0311] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each a is independently selected from 2, 3, and 4, each b is independently selected from 2, 3, 4, 5, 6, and 7, and R 1 Independently selected from optionally substituted alkenyl groups. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 50 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 40 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 30 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 25 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 20 Alkenyl group.
[0312] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each a is 3, each b is independently selected from 2, 3, 4, 5, 6, and 7, and R 1Independently selected from optionally substituted alkenyl groups. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 50 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 40 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 30 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 25 Alkenyl. In any of the above embodiments, R 1 Independently selected from arbitrarily substituted C5-C 20 Alkenyl group.
[0313] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each a is 3, each b is independently selected from 2, 3, 4, 5, 6, and 7, and each R 1 For optional substituted C5-C 20 Alkenyl group.
[0314] In embodiments of the present invention (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each a is 3, each b is 7, and each R 1 For optional substituted C5-C 20 Alkenyl group.
[0315] In some implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') In the compounds of I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is 2. In some implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') In the compounds of I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is 3.In some implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') In the compounds of I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, each a is 4.
[0316] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') In any of the following compounds, (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), each a is the same.
[0317] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') The compounds of (a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or pharmaceutically acceptable salts thereof, wherein each a is different.
[0318] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is independently selected from 2, 3, 4, 5, 6, and 7.
[0319] In some embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is 2. In some embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is 3. In some embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is 4. In some embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is 5. In some embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is 6. In some embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is 7.
[0320] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is the same.
[0321] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), or (VII'), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), or pharmaceutically acceptable salts thereof), each b is different.
[0322] In the implementation plan, A 1 Selected from and The left side of each described structure is adjacent to -(CH2). a - Combination.
[0323] In the implementation plan, A 1 for The left side of each described structure is adjacent to -(CH2). a -Combination. In the implementation plan, A 1 for The left side of each described structure is adjacent to -(CH2). a -Combination. In the implementation plan, A 1 It is -SS-.
[0324] In the implementation plan, Z 1 Selected from and The right side of each described structure is related to -(CH2). a - Combination.
[0325] In the implementation plan, Z 1 for The right side of each described structure is related to -(CH2). a -Combination. In the implementation plan, Z 1 for The right side of each described structure is related to -(CH2). a -Combination. In the implementation plan, Z 1 It is -SS-.
[0326] In the implementation plan, A 1 for The left side of each described structure is adjacent to -(CH2). a - Combined, and Z 1 for The right side of each described structure is related to -(CH2). a - Combination.
[0327] In implementation plan A 1 for The left side of each described structure is adjacent to -(CH2). a - Combined, and Z 1 for The right side of each described structure is related to -(CH2). a - Combination.
[0328] In the implementation plan, A 1 for The left side of each described structure is adjacent to -(CH2). a - Combined, and Z 1 It is -SS-.
[0329] In the implementation plan, A 1 and Z 1 Each is -SS-.
[0330] In embodiments of the present invention (e.g., a) formula (III'), (V'), (VI'), (VII'), (III), (V), (VI), or (VII), or b) formula (III'z), (V'z), (VI'z), (VII'z), (IIIz), (Vz), (VIz), or (VIIz), or a pharmaceutically acceptable salt thereof), R A and R B Same, and R C and R D same.
[0331] In embodiments of the present invention (e.g., a) formula (III'), (V'), (VI'), (VII'), (III), (V), (VI), or (VII), or b) formula (III'z), (V'z), (VI'z), (VII'z), (IIIz), (Vz), (VIz), or (VIIz), or a pharmaceutically acceptable salt thereof), R A and R C Same, and R B and R D same.
[0332] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 same.
[0333] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 different.
[0334] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Selected independently from: and
[0335] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Selected independently from: and
[0336] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Selected independently from: and
[0337] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1Independently selected from optionally substituted alkyl, optionally substituted alkenyl, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl or -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl.
[0338] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 50 Alkyl groups, optionally substituted C5-C 50 alkenyl, optionally substituted C5-C 50 alkynyl group, -optionally substituted C2-C 25 Alkyl-(C=O)-O-optionally substituted C2-C 25 Alkyl, or - optionally substituted C2-C 25 Alkyl-O-(C=O)-optionally substituted C2-C 25 alkyl.
[0339] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 40 Alkyl groups, optionally substituted C5-C 40 alkenyl, optionally substituted C5-C 40 alkynyl group, -optionally substituted C2-C 20 Alkyl-(C=O)-O-optionally substituted C2-C 20 Alkyl, or - optionally substituted C2-C 20Alkyl-O-(C=O)-optionally substituted C2-C 20 alkyl.
[0340] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 30 Alkyl groups, optionally substituted C5-C 30 alkenyl, optionally substituted C5-C 30 alkynyl group, -optionally substituted C2-C 15 Alkyl-(C=O)-O-optionally substituted C2-C 15 Alkyl, or - optionally substituted C2-C 15 Alkyl-O-(C=O)-optionally substituted C2-C 15 alkyl.
[0341] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 25 Alkyl groups, optionally substituted C5-C 25 alkenyl, optionally substituted C5-C 25 alkynyl group, -optionally substituted C2-C 15 Alkyl-(C=O)-O-optionally substituted C2-C 15 Alkyl, or - optionally substituted C2-C 15 Alkyl-O-(C=O)-optionally substituted C2-C 15 alkyl.
[0342] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 20 Alkyl groups, optionally substituted C5-C 20 alkenyl, optionally substituted C5-C 20 alkynyl group, -optionally substituted C2-C 10 Alkyl-(C=O)-O-optionally substituted C2-C 10 Alkyl, or - optionally substituted C2-C 10 Alkyl-O-(C=O)-optionally substituted C2-C 10 alkyl.
[0343] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from optionally substituted alkyl groups. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C50 Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 40 Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 30 Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 25Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 20 alkyl.
[0344] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or (VII), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from optionally substituted alkenyl groups. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 50Alkenyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 40 Alkenyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 30 Alkenyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 25Alkenyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 20 Alkenyl group.
[0345] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from optionally substituted alkynyl groups. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 50Alkyne group. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 40 Alkyne group. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 30 Alkyne group. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 25Alkyne group. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from arbitrarily substituted C5-C 20 Alkyne group.
[0346] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted alkyl-(C=O)-O-optionally substituted alkyl. In any of the above embodiments (e.g. a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted C2-C 25 Alkyl-(C=O)-O-optionally substituted C2-C 25Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted C2-C 20 Alkyl-(C=O)-O-optionally substituted C2-C 20 Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted C2-C 15 Alkyl-(C=O)-O-optionally substituted C2-C 15 Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted C2-C 10 Alkyl-(C=O)-O-optionally substituted C2-C 10 alkyl.
[0347] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted alkyl-O-(C=O)-optionally substituted alkyl. In any of the above embodiments (e.g. a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted C2-C 25 Alkyl-O-(C=O)-optionally substituted C2-C 25 Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted C2-C 20 Alkyl-O-(C=O)-optionally substituted C2-C 20Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted C2-C 15 Alkyl-O-(C=O)-optionally substituted C2-C 15 Alkyl. In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from - optionally substituted C2-C 10 Alkyl-O-(C=O)-optionally substituted C2-C 10 alkyl.
[0348] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), each R 1 Independently selected from C8H 17 C 10 H 21 C 12 H 25 C 14 H 29 C16 H 33 C 18 H 37 C 18 H 35 C 18 H 33 and C 18 H 31 .
[0349] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), R 1 C8H 17 .
[0350] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), R 1 C 10 H 21 .
[0351] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), R 1 C12 H 25 .
[0352] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), R 1 C 14 H 29 .
[0353] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), R 1 C 16 H 33 .
[0354] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), R 1 C 18 H 37 .
[0355] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), R 1 C 18 H 35 .
[0356] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), R 1 C 18 H 33 .
[0357] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI) or (VII), or b) compounds of formula (I'a), (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz) or (VIIz), or pharmaceutically acceptable salts thereof), R 1 C 18 H 31 .
[0358] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IVa), (IIb), (Ic), (IIc) or (IVc), or b) compounds of formula (Id), (IId), (IVd), (I'a), (II'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IVaz), (IIbz), (Icz), (IIcz) or (IVcz), or pharmaceutically acceptable salts thereof), each R 2 same.
[0359] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IVa), (IIb), (Ic), (IIc) or (IVc), or b) compounds of formula (Id), (IId), (IVd), (I'a), (II'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IVaz), (IIbz), (Icz), (IIcz) or (IVcz), or pharmaceutically acceptable salts thereof), each R 2 different.
[0360] In any of the above embodiments (e.g., a) compounds of formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IVa), (IIb), (Ic), (IIc) or (IVc), or b) compounds of formula (Id), (IId), (IVd), (I'a), (II'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IVaz), (IIbz), (Icz), (IIcz) or (IVcz), or pharmaceutically acceptable salts thereof), R 2 At least two of them are the same.
[0361] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B Same, and R 2C and R 2D same.
[0362] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc) or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B Same, and R 2C and R 2D different.
[0363] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B Same, and R 2C and R 2D same.
[0364] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C Same, and R 2B and R 2D same.
[0365] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') Of any one of the following compounds, or pharmaceutically acceptable salts thereof, R 2 Or each R 2A R 2B R 2C and R 2D Selected independently from: and
[0366] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') Of any one of the following compounds, or pharmaceutically acceptable salts thereof, R 2 Or each R 2A R 2B R 2C and R 2D Selected independently from: and
[0367] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') Of any one of the following compounds, or pharmaceutically acceptable salts thereof, R 2 Or each R 2A R 2B R 2C and R 2D Selected independently from: and
[0368] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') Of any one of the following compounds, R is a (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof. 2 Or each R 2A R 2B R 2C and R 2DIndependently selected from optionally substituted alkyl groups, optionally substituted alkenyl groups, and optionally substituted alkyl groups. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I'a), (I'b), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), (VIc), (VIc), or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I'b), (IIc), (IIId), (IVd), (Vc ...VId), (I'a), (I'b), (I'b), (IIc), (IIId), (IVd), (Vc), (VId), (VId), (I'a), (I'b), (I'b), (I Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2DIndependently selected from optionally substituted alkyl groups. In embodiments (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc), or (VIIc), or b) formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a) (II'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz) compounds, or pharmaceutically acceptable salts thereof), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 50Alkyl groups. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I... Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 40Alkyl groups. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I... Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 30Alkyl groups. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I... Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 25 Alkyl group. In any of the above embodiments, R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 20 alkyl.
[0369] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2DIndependently selected from optionally substituted alkenyl groups. In the above embodiments (e.g. a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 50Alkenyl. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 40Alkenyl. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 30Alkenyl. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 25Alkenyl. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 20 Alkenyl group.
[0370] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2DIndependently selected from optionally substituted alkynyl groups. In the above embodiments (e.g. a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 50Alkyne group. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 40Alkyne group. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 30Alkyne group. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 25Alkyne group. In the above embodiments (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 20 Alkyne group.
[0371] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2DIndependently selected from optionally substituted acyl groups. In the above embodiments (e.g. a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 50Acyl group. In the above embodiments (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 40Acyl group. In the above embodiments (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 30Acyl group. In the above embodiments (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 25Acyl group. In the above embodiments (e.g., a) formula (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formula (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from arbitrarily substituted C5-C 20 Acyl group.
[0372] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 Or each R 2A R 2B R 2C and R 2D Independently selected from C8H 17 C 10 H 21 C 12 H 25 C 14 H 29 C 16 H 33 C 16 H 31 C 16 H 29 and C 16 H 27 .
[0373] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 or R 2A R 2B R 2C and R 2D At least one of them is C8H 17 .
[0374] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 or R 2A R 2B R 2C and R 2D At least one of them is C 10 H 21 .
[0375] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 or R 2A R 2B R 2C and R 2D At least one of them is C 12 H 25 .
[0376] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 or R 2A R 2B R 2C and R 2D At least one of them is C 14 H 29 .
[0377] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 or R 2A R 2B R 2C and R 2D At least one of them is C 16 H 33 .
[0378] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 or R 2A R 2B R 2C and R 2D At least one of them is C 16 H 31 .
[0379] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (II') any of the following compounds, or pharmaceutically acceptable salts thereof, R2 or R 2A R 2B R 2C and R 2D At least one of them is C 16 H 29 .
[0380] In the above implementation schemes (e.g., a) formulas (I'), (II'), (III'), (IV'), (V'), (VI'), (VII'), (I), (II), (III), (IV), (V), (VI), (VII), (Ia), (IIa), (IIIa), (IVa), (Va), (VIa), (VIIa), (IIb), (IIIb), (VIb), (Ic), (IIc), (IIIc), (IVc), (Vc), (VIc) or (VIIc), or b) formulas (Id), (IId), (IIId), (IVd), (Vd), (VId), (VIId), (I'a), (I') Of any one of the following compounds, or pharmaceutically acceptable salts thereof: (I'a), (III'a), (I'z), (II'z), (III'z), (IV'z), (V'z), (VI'z), (VII'z), (Iz), (IIz), (IIIz), (IVz), (Vz), (VIz), (VIIz), (Iaz), (IIaz), (IIIaz), (IVaz), (Vaz), (VIaz), (VIIaz), (IIbz), (IIIbz), (VIbz), (Icz), (IIcz), (IIIcz), (IVcz), (Vcz), (VIcz), or (VIIcz), R 2 or R 2A R 2B R 2C and R 2D At least one of them is C 16 H 27 .
[0381] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (III'a), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B C 10 H 21 .
[0382] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (III'a), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A for And R 2B for
[0383] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2C and R 2D C 10 H 21 .
[0384] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2C and R 2D for
[0385] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2C for And R 2D for
[0386] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (III'a), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B C 16 H 31 .
[0387] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2C and R 2D C 16 H 31 .
[0388] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B C 10 H 21 And R 2C and R 2D C 16 H 31 .
[0389] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B C 16 H 31 And R 2C and R 2D C 10 H 21 .
[0390] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C for
[0391] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2B and R 2D for
[0392] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C for
[0393] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2B and R 2D for
[0394] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R2A and R 2C C 16 H 31 .
[0395] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2B and R 2D C 16 H 31 .
[0396] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C for And R 2B and R 2D C 16 H 31 .
[0397] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C for And R 2B and R 2D for
[0398] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C C 16 H 31 And R 2B and R 2D for
[0399] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B for R 2C for And R 2D for
[0400] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A for R 2B for And R 2C and R 2D for In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B The alkyl group is optionally substituted, and R 2C and R 2D The substituted alkenyl group is optional.
[0401] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2B The alkenyl group is optionally substituted, and R 2C and R 2D The alkyl group is optionally substituted.
[0402] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C For -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl, and R 2B and R 2D The substituted alkenyl group is optional.
[0403] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), R 2A and R 2C The alkenyl group is optionally substituted, and R 2B and R 2D -Optionally substituted alkyl-(C=O)-O-Optionally substituted alkyl.
[0404] In embodiments of the present invention (e.g., a) formula (IIIa), (Va), (VIa), (VIIa), (IIIb), (VIb), (IIIc), (Vc), (VIc), or (VIIc), or b) formula (IIId), (Vd), (VId), (VIId), (III'a), (IIIaz), (Vaz), (VIaz), (VIIaz), (IIIbz), (VIbz), (IIIcz), (Vcz), (VIcz), or (VIIcz), or a pharmaceutically acceptable salt thereof), each R 2A R 2B R 2C and R 2D Choose independently from: and
[0405] In the embodiments, the optionally substituted alkyl group is an alkyl group substituted with -CO2R" or -OCOR", wherein each example of R" is independently C1-C1. 20 Aliphatic (e.g., a) C1-C 20 Alkyl, C1-C 15 Alkyl, C1-C 10 Alkyl or C1-C3 alkyl; or b) C2-C 20 (alkenyl).
[0406] In the embodiments, the optionally substituted alkyl group is an alkyl group substituted with -CO2R", wherein each example of R is independently C1-C2. 20 Aliphatic (e.g., a) C1-C 20 Alkyl, C1-C 15 Alkyl, C1-C10 Alkyl or C1-C3 alkyl; or b) C2-C 20 (alkenyl).
[0407] In embodiments, the cationic lipids of the present invention comprise compounds selected from those depicted in Table AC or pharmaceutically acceptable salts thereof.
[0408] In one embodiment, a composition is provided comprising any of the cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids, and one or more PEG-modified lipids as described in the preceding embodiments. In another embodiment, the composition is lipid nanoparticles. In another embodiment, the one or more cationic lipids constitute about 30 mol% to 60 mol% of the lipid nanoparticles. In another embodiment, the one or more non-cationic lipids constitute 10 mol% to 50 mol% of the lipid nanoparticles. In another embodiment, the one or more PEG-modified lipids constitute 1 mol% to 10 mol% of the lipid nanoparticles. In another embodiment, the cholesterol-based lipids constitute 10 mol% to 50 mol% of the lipid nanoparticles. In another embodiment, the lipid nanoparticles encapsulate nucleic acids, optionally mRNA encoding peptides or proteins. In another embodiment, the lipid nanoparticles have at least 70% mRNA encapsulation percentage. In another embodiment, the lipid nanoparticles have at least 75% mRNA encapsulation percentage. In another embodiment, the lipid nanoparticles have at least 80% mRNA encapsulation percentage. In another embodiment, the lipid nanoparticles have at least 85% mRNA encapsulation percentage. In another embodiment, the lipid nanoparticles have at least 90% mRNA encapsulation percentage. In the implementation scheme, the lipid nanoparticles have an mRNA encapsulation percentage of at least 95%.
[0409] In the embodiments, the composition of any of the foregoing embodiments is used in the therapy.
[0410] In the embodiments, the composition of any of the foregoing embodiments is used in the method of treating or preventing a disease suitable for treatment or prevention by a peptide or protein encoded by mRNA, wherein the disease is optionally (a) a protein deficiency, wherein the protein deficiency affects the liver, lungs, brain or muscles, (b) an autoimmune disease, (c) an infectious disease, or (d) cancer.
[0411] In the embodiments, the composition is administered intravenously, intrathecally, or intramuscularly, or via pulmonary delivery, optionally via nebulization. Exemplary compounds
[0412] Exemplary compounds include those described in Table AC or their pharmaceutic...
Claims
1. A compound having a structure according to formula (I'z): or a pharmaceutically acceptable salt thereof, wherein: A 1 Selected from and -SS-, where the left side of each depicted structure is the same as -(CH2) a - combination; Z 1 Selected from and -SS-, where the right side of each depicted structure is the same as -(CH2) a - combination; A 1 and Z 1 different; Each R is independently selected from: (i) Among them, each R 1 are independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl; and (ii) Among them, each R 2 are independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl; Each a is independently selected from 2, 3, 4, 5 and 6; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
2. A compound having a structure according to formula (II'z): or a pharmaceutically acceptable salt thereof, wherein: A 1 Selected from and -SS-, where the left side of each depicted structure is the same as -(CH2) a - combination; Z 1 Selected from and -SS-, where the right side of each depicted structure is the same as -(CH2) a - combination; Each R is independently selected from: (i) Among them, each R 1 are independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl; and (ii) Among them, each R 2 are independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl; Each a is independently selected from 2, 3, 4, 5 and 6; Each b is independently selected from 2, 3, 4, 5, 6 and 7; and c is 3 or 4.
3. A compound having a structure according to formula (III'z): or a pharmaceutically acceptable salt thereof, wherein: A 1 Selected from and -SS-, where the left side of each depicted structure is the same as -(CH2) a - combination; Z 1 Selected from and -SS-, where the right side of each depicted structure is the same as -(CH2) a - combination; Each R A , R B , R C and R D Independently selected from: (i) Among them, each R 1 are independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, -optionally substituted alkyl-(C=O)-O-optionally substituted alkyl, and -optionally substituted alkyl-O-(C=O)-optionally substituted alkyl; and (ii) Among them, each R 2 are independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl; R A , R B , R C and R D At least one of them is different (that is, R A , R B , R C and R D are not all the same); Each a is independently selected from 2, 3, 4, 5 and 6; and Each b is independently selected from 2, 3, 4, 5, 6 and 7.
4. The compound according to claim 1, wherein the compound has a structure according to formula (Iaz): or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 2, wherein the compound has a structure according to formula (IIaz): or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 3, wherein the compound has a structure according to formula (IIIaz): or a pharmaceutically acceptable salt thereof, wherein each R 2A , R 2B , R 2C and R 2D are independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted acyl, wherein R 2A , R 2B , R 2C and R 2D At least one of them is different (that is, R 2A , R 2B , R 2C and R 2D not all are the same).
7. A compound as claimed in any one of the preceding claims, wherein the value of a on the left side of the depicted formula is 3 and the value of a on the right side of the depicted formula is 4.
8. The compound according to any one of claims 1 to 6, wherein each a is 3.
9. A compound or a pharmaceutically acceptable salt thereof, which compound is selected from those listed in Tables AC.
10. A composition comprising a cationic lipid as claimed in any one of the preceding claims or a pharmaceutically acceptable salt thereof, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.
11. The composition according to claim 10, wherein the composition is a lipid nanoparticle, optionally a liposome.
12. The composition according to claim 11, wherein the lipid nanoparticle encapsulates mRNA encoding a peptide or protein.
13. A composition according to claim 12 for use in therapy.
14. A composition according to claim 12, for use in a method of treating or preventing a disease suitable for treatment or prevention by a peptide or protein encoded by the mRNA, optionally wherein the disease is (a) a protein deficiency, optionally wherein the protein deficiency affects the liver, lungs, brain or muscle; (b) an autoimmune disease; (c) an infectious disease; or (d) cancer.
15. The composition according to claim 13 or 14, wherein the composition is administered intravenously, intrathecally or intramuscularly, or by pulmonary delivery, optionally via nebulization.
